

Index to

VOLUME 15 1981

***PHARMACOLOGY***  
***BIOCHEMISTRY***  
***AND***  
***BEHAVIOR***



## CONTENTS

<b>Hypothalamic levels and utilization of noradrenaline and 5-hydroxytryptamine in the sodium-depleted rat.</b> MUNARO, N. and E. CHIARAVIGLIO .....	1
<b>Phencyclidine and behavior: I. Sensory-motor function, activity level, taste aversion and water intake.</b> KESNER, R. P., J. D. HARDY and L. D. CALDER .....	7
<b>Influence of diet palatability on the noradrenergic feeding response in the rat.</b> SCLAFANI, A. and J. A. TORIS .....	15
<b>Investigations on the CNS sites of action of the discriminative stimulus effects of arecoline and nicotine.</b> MELTZER, L. T. and J. A. ROSECRANS .....	21
<b>Influence of <math>\beta</math>-lipotropin fragments on responsiveness of rats to electric footshock.</b> MENS, W. B. J. and J. M. VAN REE .....	27
<b>Task-dependent ethanol effects on escape in rats bred for ethanol sensitivity.</b> BASS, M. B. and D. LESTER .....	33
<b>A within-subject comparison of the effects of morphine on lateral hypothalamic and central gray self- stimulation.</b> SCHENK, S., A. COUPAL, T. WILLIAMS and P. SHIZGAL .....	37
<b>Chlorpromazine effects on behavior under escape and fixed-time delivery of shock.</b> CLEARY, J., F. GAULT and R. SEWELL .....	43
<b>Comparison of the reinforcing properties of cocaine and procaine in rhesus monkeys.</b> JOHANSON, C. E. and T. AIGNER .....	49
<b>Behavioral and physiological measures for studying ethanol dependence in mice.</b> HUTCHINS, J. B., D. L. ALLEN, L. S. COLE-HARDING and J. R. WILSON .....	55
<b>Prolactin induces grooming in the rat: Possible involvement of nigrostriatal dopaminergic system.</b> DRAGO, F., B. BOHUS, P. L. CANONICO and U. SCAPAGNINI .....	61
<b>Behavioral effects of phenylpiperidine narcotic antagonists.</b> LEANDER, J. D. ....	65
<b>The aversive stimulus properties of repeated infusions of cocaine.</b> FOLTIN, R. W., K. L. PRESTON, G. C. WAGNER and C. R. SCHUSTER .....	71
<b>Potentiation by deprenil of l-dopa induced circling in nigral-lesioned rats.</b> HEIKKILA, R. E., F. S. CABBAT, L. MANZINO and R. C. DUVOISIN .....	75
<b>Lithium increases selective attention in rats.</b> CAPPELIEZ, P. and N. WHITE .....	81
<b>Naltrexone suppresses hyperphagia induced in the rat by a highly palatable diet.</b> APFELBAUM, M. and A. MANDENOFF .....	89
<b>Pharmacologic analysis of the postictal immobility syndrome in the rat.</b> MYSLOBODSKY, M. S., M. MINTZ and O. KOFMAN .....	93
<b>Multiple exposures to ethanol facilitate intravenous self-administration of ethanol by rats.</b> NUMAN, R.	101

<b>Suppression of drinking by naloxone in rats homo- and heterozygous for diabetes insipidus. BROWN, D. R. and S. G. HOLTZMAN</b> .....	109
<b>Naloxone blocks the effect of diazepam and meprobamate on conflict behaviour in rats. DUKA, TH., R. CUMIN, W. HAEFELY and A. HERZ</b> .....	115
<b>Inhibition of evoked dopamine release by monopropionylcadaverine <i>in vitro</i>. SALZMAN, S. K. and M. STEPITA-KLAUCO</b> .....	119
<b>Postsynaptic action by four antidepressive drugs in an animal model of depression. NAGAYAMA, H., J. N. HINGTGEN and M. H. APRISON</b> .....	125
 <b>BRIEF COMMUNICATIONS</b>	
<b>Identification of a novel class of central reward sites showing a delayed and cumulative response to opiate blockade. KATZ, R. J.</b> .....	131
<b>Use of a programmable protocol timer and data logger in the monitoring of animal behavior. MURRAY, R. B., D. E. GMERER, A. COWAN and R. J. TALLARIDA</b> .....	135
<b>Food deprivation and cocaine self-administration. DE LA GARZA, R., J. BERGMAN and C. R. HARTEL</b> .....	141
<b>Effects of phencyclidine and ketamine on punished and unpunished responding by pigeons. CHAIT, L. D., G. R. WENGER and D. E. McMILLAN</b> .....	145
<b>REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats. MOGILNICKA, E.</b> .....	149
 <b>ANNOUNCEMENTS</b> .....	153

## CONTENTS

Caffeine-induced stimulus control. WINTER, J. C. ....	157
Rapid decline of stereotyped behavior in rats during constant one week administration of amphetamine via implanted ALZET® osmotic minipumps. NIELSEN, E. B. ....	161
Activity responses to morphine and amphetamine in rats with elevated NE levels in the pons. OLDS, M. E. and J. L. FOBES ....	167
Strain-dependency in motor activity and in concentration and turnover of catecholamines in synchronized rats. LEMMER, B., G. CASPARI-IRVING and R. WEIMER ....	173
Peripherally administered serotonin decreases food intake in rats. POLLOCK, J. D. and N. ROWLAND ....	179
Alcohol withdrawal reactions after chronic intake of chlordiazepoxide and ethanol. CHAN, A. W. K., F. W. LEONG, D. L. SCHANLEY and S. M. HOWE ....	185
Alcohol sensitivity in female mice: Effect of ovariectomy. RANDALL, C. L., E. A. LOCHRY, J. W. MOSELEY and P. B. SUTKER ....	191
Mechanisms of PCA-induced hypothermia, ejaculation, salivation and irritability in rats. HUMPHRIES, C. R., G. PAXINOS and M. O'BRIEN ....	197
L-tryptophan's effects on mousing killing, feeding, drinking, locomotion, and brain serotonin. GIBBONS, J. L., G. A. BARR, W. H. BRIDGER and S. F. LEIBOWITZ ....	201
Consumption of intoxicating beverages by rats and mice exhibiting high and low preferences for ethanol. YORK, J. L. ....	207
Buprenorphine self-administration by rhesus monkey. MELLO, N. K., M. P. BREE and J. H. MENDELSON ....	215
The effects of pimozide and of reward omission on fixed-interval behavior of rats maintained by food and electrical brain stimulation. GREENSHAW, A. J., D. J. SANGER and D. E. BLACKMAN ....	227
Pituitary-adrenal responses to sub-chronic treatment with phenobarbital and/or phenytoin (diphenylhydantoin) in rats. TORRELLAS, A., C. GUAZA, J. BORRELL and S. BORRELL ..	235
Biphasic locomotor response to intra-accumbens dopamine in a nonhuman primate. JONES, D. L., S. L. BERG, R. L. DORRIS and R. E. DILL ....	243
Behavioural effects of etiracetam in rats. WOLTHUIS, O. L. ....	247
Intracerebral administration of naloxone and drinking in water-deprived rats. SIVIY, S. M., F. BERMUDEZ-RATTONI, G. A. ROCKWOOD, C. M. DARGIE and L. D. REID ....	257
The antidipsogenic action of peripheral prostaglandin E <sub>2</sub> . KENNEY, N. J., K. E. MOE and K. M. SKOOG ....	263
Genetic influences on cholinergic drug response. MARKS, M. J., D. M. PATINKIN, L. D. ARTMAN, J. B. BURCH and A. C. COLLINS ....	271

A novel female influences $\Delta^9$ -THC effects on plasma hormone levels in male mice. DALTERIO, S., A. BARTKE and D. MAYFIELD .....	281
Behavioral effects of deanol, of hemicholinium and of their interaction. RUSSELL, R. W. and D. J. JENDEN .....	285
Long-term memory: Disruption by inhibitors of protein synthesis and cytoplasmic flow. FLOOD, J. F., D. W. LANDRY, E. L. BENNETT and M. E. JARVIK .....	289
Increased urination following p-chloroamphetamine. STEIN, J. M., M. J. WAYNER and K. M. KANTAK .....	297
(-)- <i>threo</i> -Chlorocitric acid: A novel anorectic agent. SULLIVAN, A. C., W. DAIRMAN and J. TRISCARI .....	303
Studies on the mechanism of action of a novel anorectic agent, (-)- <i>threo</i> -chlorocitric acid. TRISCARI, J. and A. C. SULLIVAN .....	311
 <i>BRIEF COMMUNICATIONS</i>	
Naloxone reduces fluid intake in rats with open gastric fistulas. ROCKWOOD, G. A., S. M. SIVIY and L. D. REID .....	319
Relationship between caffeine discrimination and caffeine plasma levels. MODROW, H. E., F. A. HOLLOWAY, H. D. CHRISTENSEN and J. M. CARNEY .....	323
Use of operant response duration to distinguish the effects of haloperidol from nonreward. FAUSTMAN, W. O. and S. C. FOWLER .....	327
 <i>ANNOUNCEMENTS</i> .....	331

## CONTENTS

<b>Thirst in the rat after ligation of the inferior vena cava: Role of angiotensin II.</b> MANN, J. F. E., A. K. JOHNSON, W. RASCHER, J. GENEST and D. GANTEN .....	337
<b>Dietary tryptophan reversal of septal lesion and 5,7-DHT lesion elicited shock-induced fighting.</b> KANTAK, K. M., L. R. HEGSTRAND and B. EICHELMAN .....	343
<b>Effect of minor tranquilizers, tryptamine antagonists and amphetamine on behavior punished by brain stimulation.</b> MORATO DE CARVALHO, S., J. C. DE AGUIAR and F. G. GRAEFF .....	351
<b>d-Amphetamine and phencyclidine alone and in combination: Effects on fixed-ratio and interresponse-time-greater-than-t responding of rats.</b> POLING, A., J. CLEARY, K. JACKSON and S. WALLACE .....	357
<b>Effect of brain serotonin level on induced hippocampal paroxysmal activity in rats.</b> CAVALHEIRO, E. A., E. ELISABETSKY and C. J. R. CAMPOS .....	363
<b>D-Glutamine produces seizures and retrograde amnesia in the chick.</b> DAVIS, J. L. and A. CHERKIN .....	367
<b>Effect of fenfluramine and nicotine upon a stimulant-depressant continuum.</b> SCHECHTER, M. D. ..	371
<b>Multiple receptor sites mediate sweetness: Evidence from cross adaptation.</b> SCHIFFMAN, S. S., H. CAHN and M. G. LINDLEY .....	377
<b>Aversive stimulus properties of scopolamine.</b> MACMAHON, S. W., N. M. BLAMPIED and R. N. HUGHES .....	389
<b>Delayed emergence of antidepressant efficacy following withdrawal in olfactory bulbectomized rats.</b> NOREIKA, L., G. PASTOR and J. LIEBMAN .....	393
<b>Chronic amphetamine: Tolerance and reverse tolerance reflect different behavioral actions of the drug.</b> LEITH, N. J. and R. KUCZENSKI .....	399
<b>Chronic amphetamine: Is dopamine a link in or a mediator of the development of tolerance and reverse tolerance?</b> KUCZENSKI, R. and N. J. LEITH .....	405
<b>Clozapine effects on responding maintained under shock presentation and shock termination schedules.</b> BACOTTI, A. V. ....	415
<b>Blockade by naltrexone of analgesia produced by stimulation of the dorsal raphe nucleus.</b> SWAJKOSKI, A. R., D. J. MAYER and J. H. JOHNSON .....	419
<b>Locomotor activity in morphine-treated rats: Effects of and comparisons between cocaine, procaine, and lidocaine.</b> WIECHMAN, B. E., T. E. WOOD and G. R. SPRATTO .....	425
<b>The effects of pimozide on the consumption of a palatable saccharin-glucose solution in the rat.</b> XENAKIS, S. and A. SCLAFANI .....	435
<b>Effects of bromocriptine in developing rat pups after 6-hydroxydopamine.</b> SHAYWITZ, B. A., S. V. LIPTON, M. H. TEICHER, D. J. COHEN, G. M. ANDERSON, D. K. BATTER and J. G. YOUNG .....	443

Properties of mercury and selenium in a high-molecular weight substance in rabbit tissues formed by simultaneous administration. NAGANUMA, A. and N. IMURA .....	449
Ethanol-Metrecal diets: I. Effects of different levels of ethanol-derived kilocalories on consumption of diet, body weight and grams of ethanol ingested. TOMBAUGH, T. N. and J. W. TOMBAUGH .....	455
Ethanol-Metrecal diets: II. Failure to obtain impaired performance on a series of appetitively and aversively motivated tasks. TOMBAUGH, T. N. ....	463
Cross-tolerance to phenobarbital following chronic ethanol polydipsia. LAU, C. E., M. TANG and J. L. FALK .....	471
Opioid modulation of ingestive behavior. JALOWIEC, J. E., J. PANKSEPP, A. J. ZOLOVICK, N. NAJAM and B. H. HERMAN .....	477
Low dose cocaine self-administration by naive rats: Effects of body weight and a fixed-time one minute food delivery schedule. PAPASAVA, M., T. P. S. OEI and G. SINGER .....	485
Effects of cycloheximide and puromycin on learning and retention in the cockroach, <i>P. americana</i> . BARRACO, D. A., K. L. LOVELL and E. M. EISENSTEIN .....	489
Oxidation of alcohol in free-moving mice from high and low preference strains. DUCKETT, S., C. W. SCHNEIDER and R. A. HARTLINE .....	495
Analgesia following microinjection of phosphodiesterase inhibitors at brainstem sites. LEVY, R. A. and B. D. GOLDSTEIN .....	501
Drug and food-deprivation modulation of activity in rats given chronic dietary lead: Significance of type of activity measure. YAMAMOTO, B. K. and C. L. KUTSCHER .....	505
 <i>BRIEF COMMUNICATIONS</i>	
Naloxone potentiates shock-induced aggressive behavior in mice. PUGLISI-ALLEGRA, S. and A. OLIVERIO .....	513
Long term catheterization of the lumbar epidural space in rats. VAN DEN HOOGEN, R. H. W. M. and F. C. COLPAERT .....	515
Regional changes in brain cholinergic enzyme activities after bilateral olfactory bulbectomy in relation to mouse-killing behavior by rats. YOSHIMURA, H. ....	517
Distinctions between stereotyped sniffing and licking in rats with methamphetamine and apomorphine. SCHULZ, E. M., J. W. WRIGHT and J. W. HARDING .....	521
 <i>ANNOUNCEMENTS</i> .....	 525



## CONTENTS

Transfer of pentylenetetrazol sensitization to amygdaloid kindling. CAIN, D. P. ....	533
Effect of some cholinergic drugs on the conditioned pole jump response in rats. BHARGAVA, V. K. and C. P. PUSHPAVATI .....	537
Ethanol reinforced behavior assessed with a concurrent schedule. ROEHRS, T. A. and H. H. SAMSON .....	539
(RS)- $\alpha$ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid: Wet dog shakes, catalepsy and body temperature changes in rats. TURSKI, W., L. TURSKI, S. J. CZUCZWAR and Z. KLEINROK .....	545
Blood glucose and body temperature alterations induced by ethanol in rats submitted to different levels of food deprivation. OLIVEIRA DE SOUZA, M. L. and J. MASUR .....	551
A probable role for norepinephrine in feeding after hypothalamic injection of morphine. TEPPERMAN, F. S., M. HIRST and C. W. GOWDEY .....	555
Sensitization to the behavioral effects of cocaine: Modification by Pavlovian conditioning. HINSON, R. E. and C. X. POULOS .....	559
Periventricular preoptic-hypothalamic lesions: Effects on isoproterenol-induced thirst. LIND, R. W. and A. K. JOHNSON .....	563
GABAergic modulation of learned helplessness. PETTY, F. and A. D. SHERMAN .....	567
Effect of early and later colony housing on oral ingestion of morphine in rats. ALEXANDER, B. K., B. L. BEYERSTEIN, P. F. HADAWAY and R. B. COAMBS .....	571
A sensitive open field measure of anxiolytic drug activity. BRITTON, D. R. and K. T. BRITTON .....	577
Pentobarbital induces a naloxone-reversible decrease in mesolimbic self-stimulation threshold. SEEGER, T. F., K. R. CARLSON and J. M. NAZZARO .....	583
Role of serotonin in the nicotine-induced depression of the brainstem auditory evoked response. BHARGAVA, V., A. SALAMY and S. SHAH .....	587
Stereoselective effects of opiate agonists and antagonists on ingestive behavior in rats. LOWY, M. T., C. STARKEY and G. K. W. YIM .....	591
Amnesia due to $\beta$ -antagonists in a passive avoidance task in the chick. STEPHENSON, R. M. and R. J. ANDREW .....	597
Benzodiazepines decrease grooming in response to novelty but not ACTH or $\beta$ -endorphin. DUNN, A. J., A. L. GUILD, N. R. KRAMARCY and M. D. WARE .....	605
Use of a fixed consecutive number schedule of reinforcement to investigate the effects of pimozide on behavior controlled by internal and external stimuli. SZOSTAK, C. and T. N. TOMBAUGH .....	609
Conditioned defensive burying: A new paradigm for the study of anxiolytic agents. TREIT, D., J. P. J. PINEL and H. C. FIBIGER .....	619

<b>An assessment of spectral analysis of amphetamine-induced behavior.</b> ELLINWOOD, E. H., JR., D. W. MOLTER and K. A. STAUDERMAN .....	627
<b>Time-dependent retention deficits induced by post-training injections of atropine into the caudate nucleus.</b> PRADO-ALCALÁ, R. A., L. SIGNORET and M. FIGUEROA .....	633
<b>Apparent lack of tolerance in the Formalin test suggests different mechanisms for morphine analgesia in different types of pain.</b> ABBOTT, F. V., K. B. J. FRANKLIN, R. J. LUDWICK and R. MELZACK .....	637
<b>Neonatal lead exposure: Effects on development of behavior and striatal dopamine neurons.</b> JASON, K. M. and C. K. KELLOGG .....	641
 <i>BRIEF COMMUNICATIONS</i>	
<b>Morphine conditioned taste aversion reversed by periaqueductal gray lesions.</b> BLAIR, R. and Z. AMIT	651
<b>Pimozide attenuates acquisition of lever-pressing for food in rats.</b> WISE, R. A. and H. V. SCHWARTZ .....	655
<b>Body temperature of rats after prostaglandins E<sub>2</sub> and F<sub>2α</sub> and their precursor.</b> SPŁAWIŃSKI, J., B. WOJTASZEK and Z. GÓRKA .....	657
<b>Antagonism of the behavioral effects of 2,5-dimethoxy-4-methylamphetamine (DOM) and quipazine by metergoline.</b> COMMISSARIS, R. L. and R. H. RECH .....	659
<b>The use of fluoride for the prevention of chronic intracranial implant dislodgment.</b> YAMAMOTO, B. K. and C. L. KUTSCHER .....	663
 <i>ANNOUNCEMENTS</i> .....	665

## CONTENTS

Short-term memory: The role of d-amphetamine. KESNER, R. P., R. A. BIERLEY and P. PEBBLES .....	673
Naltrexone and the tail flick reflex. ADVOKAT, C. ....	677
Pharmacologic analysis of sodium valproate-induced suppression of secondary components of visual evoked potentials in albino rats. MYSLOBODSKY, M. S. and M. MORAG .....	681
Do cholinomimetics specifically antagonize rotational behavior? WESTERMANN, K. H. ....	687
The effect of cyproterone acetate on shock elicited aggression in rats. PRASAD, V. and M. H. SHEARD .....	691
Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. CRAWLEY, J. N. ....	695
Amphetamine and apomorphine induced stereotyped behavior in adult pigeons. GOODMAN, I. J. ....	701
Dopamine induced changes in L-fucose incorporation into proteins of rat hippocampus and corpus striatum during postnatal development. LÖSSNER, B., R. JORK and H. MATTHIES ..	705
Serotonergic and dopaminergic effects on yawning in the cat. MARINI, J. L. ....	711
Effects of repeated DSIP and DSIP-P administration on the circadian locomotor activity of rats. GRAF, M., H. CHRISTEN, H. J. TOBLER, P. F. MAIER and G. A. SCHOENENBERGER .....	717
Brain concentrations of phenobarbital and behavioral activation or depression. MIDDAUGH, L. D., L. A. BLACKWELL, W. O. BOGGAN and J. W. ZEMP .....	723
Strain dependent effects of the enkephalin analogue FK 33-824 on locomotor activity in mice. CASTELLANO, C. ....	729
The effect of prostaglandins (PGE <sub>2</sub> and PGF <sub>2α</sub> ) on food intake in rats. LEVINE, A. S. and J. E. MORLEY .....	735
Differential effects of alpha-adrenergic antagonists on tonic immobility in domestic fowl. HENNIG, C. W., E. B. CARL, S. ALDRICH, J. K. FAZIO and C. A. HUGHES .....	739
Drug alterations of punished responding after chlordiazepoxide: Possible screen for agents useful in minimal brain dysfunction. PAPPAS, B. A., R. A. VOGEL, J. H. WILSON, R. A. MUELLER and G. R. BREESE .....	743
Facilitation of muricide in rats by cholinergic stimulation of the lateral hypothalamus. YOBURN, B. C., M. GLUSMAN, M. POTEAL and L. SKAREDOFF .....	747
Heroin and morphine: Aversive and analgesic effects in rats. SWITZMAN, L., T. HUNT and Z. AMIT .....	755

Antagonism of estrogen-induced lordosis by corticosterone in adrenalectomized-ovariectomized female rats and mice. DECATANZARO, D., R. P. KNIPPING and B. B. GORZALKA . . . .	761
Differential effects of drug treatments on nose-poke and bar-press self-stimulation. GERHARDT, S. and J. M. LIEBMAN . . . . .	767
Development of opiate tolerance in the chick embryo. NEWBY-SCHMIDT, M. B. and S. NORTON	773
Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. MOSS, D. E., S. B. McMASTER and J. ROGERS . . . . .	779
Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. AHLENIUS, S., K. LARSSON, L. SVENSSON, S. HJORTH, A. CARLSSON, P. LINDBERG, H. WIKSTRÖM, D. SANCHEZ, L.-E. ARVIDSSON, U. HACKSELL and J. L. G. NILSSON . . . . .	785
Facilitation of kindling by convulsions induced by cocaine or lidocaine but not pentylenetetrazol. STRIPLING, J. S. and C. HENDRICKS . . . . .	793
The effects of pentobarbital upon auditory and visual thresholds in the baboon. HIENZ, R. D., S. E. LUKAS and J. V. BRADY . . . . .	799
Effects of phencyclidine, <i>d</i> -amphetamine and pentobarbital on schedule-controlled behavior in rats. SEGAL, S. A., J. M. MOERSCHBAECHER and D. M. THOMPSON . . . . .	807
Effects of phencyclidine on shock-induced aggression in rats. CLEARY, J., J. HERAKOVIC and A. POLING . . . . .	813
 <i>BRIEF COMMUNICATIONS</i>	
The effect of ethanol on wheel running in rats. DUNCAN, P. M. and A. M. BAEZ . . . . .	819
A simple intravenous catheter for use with a cranial pedestal in the rat. STRIPLING, J. S. . . . .	823
Conditioned gustatory avoidance induced by three cholinergic agents. PRESTON, K. L. and C. R. SCHUSTER . . . . .	827
 <i>ABSTRACTS</i>	
Satellite Meeting of the International Study Group Investigating Drugs as Reinforcers (ISGIDAR) . .	829
 <i>ANNOUNCEMENTS</i> . . . . .	835

## CONTENTS

Inverse relationship between onset and duration of EEG effects of six peripherally administered peptides. MILLER, L. H., A. J. KASTIN, M. HAYES, A. STERSTE, J. GARCIA and D. H. COY .....	845
Method of sacrifice influences leucine enkephalin binding to mouse brain. CHRISTIE, M. J., G. J. ZINGARELLI and G. B. CHESHER .....	849
The correlation between swim-stress induced antinociception and [ <sup>3</sup> H] leu-enkephalin binding to brain homogenates in mice. CHRISTIE, M. J., G. B. CHESHER and K. D. BIRD .....	853
Ontogeny of fenfluramine and amphetamine anorexia compared in rat pups. LESHEM, M. ....	859
Pilocarpine, a non-hallucinogenic cholinergic agonist, elicits limb flicking in cats. MARINI, J. L. ....	865
Blockade of 5-HTP reduction of ethanol drinking with the decarboxylase inhibitor, Ro 4-4602. GELLER, I., R. J. HARTMANN and F. S. MESSIHA .....	871
Effects of caffeine on tactile startle in rats. WARD, H. W., T. POLLARE and M. A. GEYER .....	875
Renin-aldosterone axis in ethanol intoxication. NIEMINEN, M. M., F. FYHRQUIST, J. LINKOLA, I. TIKKANEN and K. TONTTI .....	879
The effects of melatonin on open field behavior. GOLUS, P. and M. G. KING .....	883
Withdrawal-like symptoms in young and adult rats maternally exposed to methadone. ZAGON, I. S. and P. J. McLAUGHLIN .....	887
The effects of quipazine, fenfluramine and apomorphine on the morphine potentiation of tonic immobility. WALLNAU, L. B. ....	895
Chlorpromazine and brain-stimulation reward: Potentiation of effects by naloxone. ESPOSITO, R. U., W. PERRY and C. KORNETSKY .....	903
Comparative stimulus properties of two fractions of the coca leaf ( <i>E. coca</i> ). BEDFORD, J. A., G. L. NAIL, H. N. ELSOHLY, M. C. WILSON and C. E. TURNER .....	907
Effect of an amnesic dose of reserpine, syrosingopine or guanethidine on the levels of whole brain dopamine and norepinephrine in the mouse. BROWN, O. M., T. PALFAI and L. WICHLINSKI .....	911
Pimozide attenuates conditioned taste preferences induced by self-stimulation in rats. ETTENBERG, A. and N. WHITE .....	915
Low doses of naloxone and MIF-1 peptides increase fluid consumption in rats. OLSON, R. D., R. C. FERNANDEZ, A. J. KASTIN, G. A. OLSON, S. W. DELATTE, T. K. VON ALMEN, D. G. ERICKSON, D. C. HASTINGS and D. H. COY .....	921
Enhancing effect of methamphetamine on ambulatory activity produced by repeated administration in mice. HIRABAYASHI, M. and M. R. ALAM .....	925

Repeated administration of pergolide to rats attenuates the acute elevation of serum corticosterone by pergolide. FULLER, R. W. and H. D. SNODDY .....	933
Sleep suppressant action of quipazine: Relation to central serotonergic stimulation. FORMAL, C. and M. RADULOVACKI .....	937
Ethanol-induced changes in tyrosine hydroxylase activity in brains of mice selectively bred for differences in sensitivity to ethanol. BAIZER, L., J. M. MASSERANO and N. WEINER .....	945
Brain monoamine oxidase activity after in vivo-chronic iprindole treatment. ORTEGA-CORONA, B. G., J. CARRANZA, A. SOSA, P. GUZMÁN-AMAYA, N. S. ESPARZA-AVALOS and G. CASTRO-OSUNA .....	951
Permeability of blood-brain barrier to DSIP peptides. KASTIN, A. J., C. NISSEN and D. H. COY .....	955
Facilitation of sexual receptivity in the rat by an ovulation-inhibiting analog of LHRH. ZADINA, J. E., A. J. KASTIN, L. A. FABRE and D. H. COY .....	961
The effects of acute administration of diazepam on the binding of [ <sup>3</sup> H]-diazepam and [ <sup>3</sup> H]-GABA to rat cortical membranes. COUPET, J., C. E. RAUH, A. S. LIPPA and B. BEER .....	965
Radioimmunoassay of DSIP-like material in human blood: Possible protein binding. KASTIN, A. J., P. F. CASTELLANOS, W. A. BANKS and D. H. COY .....	969
Human platelet imipramine recognition sites: Biochemical and pharmacological characterization. WENNOGLE, L. P., B. BEER and L. R. MEYERSON .....	975
 <i>BRIEF COMMUNICATIONS</i>	
Effects of MIF-1 and three related peptides on reserpine-induced hypothermia in mice. KASTIN, A. J., L. C. HONOUR and D. H. COY .....	983
Computer-aided calculation of dose response curves in behavioral pharmacology by using a nonlinear regression procedure. MORGENSTERN, R., H. FINK and R. BLUTH .....	987
 <i>INDEX TO VOLUME 15</i> .....	 993

## VOLUME 15 1981

### SUBJECT INDEX

- Abuse liability, 49
  - cocaine
  - procaine
  - reinforcing efficacy
  - Rhesus monkey
- Acetylcholinesterase activity, 517
  - choline acetyltransferase activity
  - muricide
  - olfactory bulbectomy
  - scopolamine
- Acquisition, 247
  - etiracetam
  - extinction
  - open field
  - passive avoidance
  - piracetam
  - retention
- ACTH, 605
  - benzodiazepines
  - $\beta$ -endorphin
  - grooming
- Active avoidance, 289
  - anisomycin
  - axoplasmic transport inhibition
  - colchicine
  - memory
  - passive avoidance
  - podophyllotoxin
  - protein synthesis inhibition
  - vinblastine
- Activity, 545
  - AMPA
  - body temperature
  - catalepsy
  - seizures
  - wet dog shakes
- Activity level
  - behavior, 7
  - distractability, 81
  - drinking, 7
  - ethanol, 819
  - exploration, 81
  - lithium chloride, 81
  - phencyclidine, 7
  - selective attention, 81
  - sensory-motor function, 7
  - taste aversion, 7
  - wheel-running, 819
- Activity responses, 167
  - amphetamine
  - brain catecholamines
  - 6-hydroxydopamine
  - morphine
  - norepinephrine levels
- Adrenalectomy, 761
  - corticosterone
  - estrogen-induced lordosis
  - ovariectomy
  - sexual behavior, female
- Aggression
  - apomorphine, 149
  - carbachol, 747
  - cholinergic stimulation, 747
  - head twitches, 149
  - irritability, 747
  - lateral hypothalamus, 747
  - muricide, 747
  - quipazine, 149
  - REM sleep deprivation, 149
- Alcohol and estrous cycle, 191
  - alcohol sensitivity
  - mice, female
  - ovariectomy
- Alcohol consumption, female rats, 207
  - alcohol consumption, inbred mice
  - ethanol preferences
  - pentobarbital
- Alcohol consumption, inbred mice, 207
  - alcohol consumption, female rats
  - ethanol preferences
  - pentobarbital
- Alcohol sensitivity, 191
  - alcohol and estrous cycle
  - mice, female
  - ovariectomy
- Alcohol withdrawal, 185
  - chlordiazepoxide
  - ethanol liquid diet
- Aldosterone, 879
  - ethanol
  - renin
  - sodium balance
- Alpha-adrenergic antagonists, 739
  - animal hypnosis
  - chicken
  - phentolamine
  - prazosin
  - tonic immobility
  - yohimbine
- Ambulatory activity, 925
  - learning and enhancement of drug effect
  - methamphetamine
- Aminophylline, 157
  - caffeine
  - stimulus control
- Amnesia
  - $\beta$ -antagonists, 597
  - biogenic amines, 911
  - brain catecholamine levels, 911
  - cockroach, 489

- cycloheximide, 489
- guanethidine, 911
- nadolol, 597
- passive avoidance learning, 597
- protein synthesis inhibition, 489
- puromycin, 489
- Rauwolfia alkaloids, 911
- sotalol, 597
- timolol, 597
- AMPA, 545
  - body temperature
  - catalepsy
  - hyperactivity
  - hyperthermia
  - hypoactivity
  - hypothermia
  - seizures
  - wet dog shakes
- Amphetamine
  - activity responses, 167
  - anorexia, 859
  - avian behavior, 701
  - brain catecholamines, 167
  - bupropion, 743
  - chronic administration, 399
  - dietary lead and hyperactivity, 505
  - dopaminergic function, 399
  - drug-induced stereotyped behavior, 701
  - eating, 859
  - fenfluramine, 859
  - fixed interval, 807
  - fixed ratio, 807
  - 6-hydroxydopamine, 167
  - lever press, 807
  - methylphenidate, 743
  - minimal brain dysfunction, 743
  - morphine, 167
  - multiple schedule, 807
  - neonatal lead exposure, 641
  - noepinephrine levels, 167
  - olfactory bulbectomy, 393
  - passive avoidance, 393
  - pentobarbital, 807
  - phencyclidine, 807
  - pigeon, 701
  - punished responding, 743
  - short-term memory, 673
  - tolerance, reverse tolerance and behavioral effects, 399
- d-Amphetamine
  - clorgyline, 75
  - deprenil, 75
  - l-dopa, 75
  - <sup>3</sup>H-dopamine release, 75
  - <sup>3</sup>H-dopamine uptake, 75
  - drug interaction, 357
  - lesions, 6-OHDA, 75
  - operant behavior, 357
  - Parkinsonism, 75
  - phencyclidine, 357
  - substantia nigra, 75
- Amphetamine behavior assessment, 627
  - capacitance transducer
  - spectral analysis
- Amygdaloid kindling, 533
  - pentylene-tetrazol sensitization transfer
  - seizures
- Analgesia
  - behavioral tolerance, 637
  - catatonia/catalepsy, 93
  - caudal reticular formation, 501
  - conditioned taste aversion, 755
  - convulsions, drug-induced, 93
  - convulsions, electroshock-induced, 93
  - cyclic nucleotides, 501
  - Formalin test, 637
  - heroin, 755
  - morphine, 637, 755
  - pain, 637
  - phosphodiesterase inhibitors, 501
  - postictal EEG depression, 93
  - postictal immobility, 93
  - tolerance, 637
  - tonic pain, 637
- Analgesia blockade, 419
  - dorsal raphe nucleus
  - naltrexone
  - opiate mechanisms
- Angiotensin, 563
  - anteroventral third ventricle
  - drinking
  - isoproterenol-induced thirst
  - periventricular preoptic-hypothalamic lesions
- Angiotensin II, 263
  - body temperature
  - cellular dehydration
  - conditioned taste aversion
  - drinking
  - hypovolemia
  - prostaglandins
  - water deprivation
- Animal hypnosis, 739
  - alpha-adrenergic antagonists
  - chicken
  - phenolamine
  - prazosin
  - tonic immobility
  - yohimbine
- Animal model
  - antidepressants, 695
  - anxiety, 619
  - anxiolytic drugs, 619
  - anxiolytics, 695
  - benzodiazepines and behavior, 695
  - conditioned defensive burying, 619
  - exploration, 695
  - locomotion, 695
  - neuroleptics, 695
  - sedation, 695
- Animal model, depression, 125
  - antidepressants
  - postsynaptic effects
  - presynaptic effects
  - serotonergic receptors
- Animex motimeter, 173
  - catecholamine concentration and turnover
  - circadian rhythm
  - motor activity
  - strain differences
- Anisomycin, 289
  - active avoidance
  - axoplasmic transport inhibition
  - colchicine
  - memory
  - passive avoidance
  - podophyllotoxin
  - protein synthesis inhibition
  - vinblastine
- Anorexia
  - amphetamine, 859
  - (-)-*threo*-chlorocitric acid, 303
  - eating, 859
  - fenfluramine, 859
- Antianxiety drugs, 115
  - conflict behavior
  - diazepam
  - meprobamate
  - naloxone
  - opioid peptides
- Anticipatory responding, 43
  - chlorpromazine



- escape
- fixed-time schedule
- restraint
- Antidepressants
  - amphetamine, 393
  - animal model, 695
  - animal model, depression, 125
  - anxiolytics, 695
  - benzodiazepines and behavior, 695
  - calcium, 975
  - exploration, 695
  - imipramine, 393, 975
  - locomotion, 695
  - neuroleptics, 695
  - olfactory bulbectomy, 393
  - passive avoidance, 393
  - phospholipase A, 975
  - platelets, human, 975
  - postsynaptic effects, 125
  - presynaptic effects, 125
  - receptor characterization, 973
  - sedation, 695
  - serotonergic receptors, 125
  - tricyclics, 975
- Anxiety, 619
  - animal model
  - anxiolytic drugs
  - conditioned defensive burying
- Anxiolytic drugs
  - animal model, 619
  - anxiety, 619
  - chlordiazepoxide, 577, 619
  - chlorpromazine, 619
  - conditioned defensive burying, 619
  - diazepam, 577, 619
  - eating, 577
  - ethanol, 577
  - handling, 577
  - open field test, 577
  - pentobarbital, 577, 619
- Anxiolytics, 695
  - animal model
  - antidepressants
  - benzodiazepines and behavior
  - exploration
  - locomotion
  - neuroleptics
  - sedation
- Apomorphine
  - aggression, 149
  - avian behavior, 701
  - chicks, 895
  - dopaminergic mechanisms, 895
  - drug-induced stereotyped behavior, 701
  - fenfluramine, 895
  - head twitches, 149
  - methamphetamine, 521
  - morphine, 895
  - pigeon, 701
  - quipazine, 149, 895
  - REM sleep deprivation, 149
  - serotonergic model, 895
  - stereotyped licking and sniffing, 521
  - tonic immobility, 895
- Apparatus
  - Animex motimeter, 173
  - capacitance transducer, 627
  - intravenous catheter, 823
  - microcomputerized protocol timer, 135
- Arachidonic acid, 657
  - body temperature
  - nucleus reticularis pontis caudalis
- Arecoline, 21
  - central nervous system
  - drug discrimination
- hippocampus
- nicotine
- reticular formation
- Atropine
  - caudate nucleus, 633
  - cholinergic inhibition, 633
  - conditioned avoidance, 537
  - conditioned pole jump response, 537
  - conditioned taste aversion, 827
  - learning and retention, 633
  - memory, 633
  - muscarinic receptors, 537
  - passive avoidance, 633
- Auditory threshold, 799
  - baboon
  - pentobarbital
  - primate
  - reaction time
  - visual threshold
- Aversive brain stimulation, 351
  - amphetamine
  - chlordiazepoxide
  - cyproheptadine
  - dorsal periaqueductal gray
  - methysergide
  - pentobarbital
- Aversive drug stimulus and location avoidance
  - scopolamine, 389
- Aversive stimuli, 71
  - cocaine
  - gustatory avoidance conditioning
- Avian behavior, 701
  - amphetamine
  - apomorphine
  - drug-induced stereotyped behavior
  - pigeon
- Avoidance, 463
  - ethanol-Metrecal
  - liquid diet
  - passive
  - shuttle
- Axoplasmic transport inhibition, 289
  - active avoidance
  - anisomycin
  - colchicine
  - memory
  - passive avoidance
  - podophyllotoxin
  - protein synthesis inhibition
  - vinblastine
- $\beta$ -Antagonists and amnesia, 597
  - nadolol
  - passive avoidance learning
  - sotalol
  - timolol
- Baboon, 799
  - auditory threshold
  - pentobarbital
  - primate
  - reaction time
  - visual threshold
- Bar press, 767
  - clonidine
  - haloperidol
  - methocarbamol
  - nose poke
  - pentobarbital
  - self-stimulation
- Behavior, 7
  - activity level
  - drinking
  - phencyclidine
  - sensory-motor function
  - taste aversion

- Behavior monitoring, 135
  - data acquisition
  - microcomputerized protocol timer
- Behavioral tolerance
  - analgesia, 637
  - Formalin test, 637
  - morphine, 637
  - naltrexone, 677
  - opiate analgesia, 677
  - pain, 637
  - tolerance, 637
  - tonic pain, 637
- Benzodiazepines
  - ACTH and excessive grooming, 605
  - $\beta$ -endorphin, 605
  - grooming, 605
  - sodium valproate, 681
  - visual evoked potentials, 681
- Benzodiazepines and behavior, 695
  - animal model
  - antidepressants
  - anxiolytics
  - exploration
  - locomotion
  - neuroleptics
  - sedation
- Bicuculline
  - GABA and learned helplessness, 567
- Biogenic amines, 911
  - amnesia
  - brain catecholamine levels
  - guanethidine
  - Rauwolfia alkaloids
- Blood-brain barrier, 955
  - DSIP peptides
  - radioimmunoassay
- Body temperature
  - AMPA, 545
  - angiotensin II, 263
  - arachidonic acid, 657
  - catalepsy, 545
  - cellular dehydration, 263
  - conditioned taste aversion, 263
  - drinking, 263
  - ethanol and food deprivation, 551
  - ethanol and starvation, 551
  - hyperactivity, 545
  - hyperglycemia, 551
  - hyperthermia, 545, 645, 657
  - hypoactivity, 545
  - hypoglycemia, 551
  - hypothermia, 657
  - hypovolemia, 263
  - prostaglandin  $E_2$ , 657
  - prostaglandin  $F_{2\alpha}$ , 657
  - prostaglandins, 263
  - seizures, 545
  - water deprivation, 263
  - wet dog shakes, 545
- Body weight, 297
  - p*-chloroamphetamine
  - defecation
  - urination
- Brain
  - amygdala, 517, 533
  - caudal reticular formation, 501
  - caudate nucleus, 633, 687
  - central gray, 37
  - cerebellum, 271, 949
  - cerebral cortex, 949
  - corpus striatum, 705
  - cortex, 271, 517, 965
  - dorsal hippocampus, 21
  - dorsal periaqueductal gray, 351
  - dorsal raphe nucleus, 419
  - globus pallidus, 687
  - hippocampus, 271, 363, 517, 705
  - hypothalamus, 1, 517, 945
  - lateral hypothalamus, 37, 257, 747
  - lateral ventricles, 257
  - medulla oblongata, 517
  - mesencephalic reticular formation, 21
  - mesencephalon, 951
  - midbrain, 271
  - neostriatum, 61, 119
  - nucleus accumbens, 243
  - nucleus reticularis pontis caudalis, 657
  - olfactory bulb, 517, 793
  - paraventricular hypothalamus, 15
  - periaqueductal gray, 651
  - periventricular preoptic-hypothalamus, 563
  - pituitary-adrenal axis, 235
  - pons, 167, 517
  - pons-medulla, 271
  - raphe nuclei, 363
  - striatum, 271, 641
  - substantia nigra, 61, 75, 687
  - tegmentum, 517
  - thalamus, 517
  - ventral tegmental area, 583
  - ventromedial hypothalamus, 15, 555
- Brain catecholamine levels, 911
  - amnesia
  - biogenic amines
  - guanethidine
  - Rauwolfia alkaloids
- Brain catecholamines, 167
  - activity responses
  - amphetamine
  - 6-hydroxydopamine
  - morphine
  - norepinephrine levels
- Brain electrical activity, 845
  - DSIP
  - endorphin
  - enkephalin
  - MSH
  - opiates
- Brain serotonin
  - drinking, 201
  - eating, 201
  - ethanol intake, 871
  - 5-hydroxytryptophan, 871
  - locomotion, 201
  - muricide, 201
  - Ro 4-4602, 871
  - tryptophan, 201
- Brain stimulation, 419
  - analgesia
  - dorsal raphe nucleus
  - naltrexone
  - opiate mechanisms
- Brain-stimulation reward
  - chlorpromazine, 903
  - conditioned taste preference, 915
  - dopamine receptor antagonism, 915
  - enkephalin, 903
  - naloxone, 903
  - pimozide, 915
  - schizophrenia, 903
  - self-stimulation, 915
- Brainstem auditory evoked response, 587
  - nicotine-induced depression
  - serotonin
- Brattleboro rat, 109
  - diabetes insipidus
  - drinking
  - naloxone
  - water deprivation
- Bromocriptine, 443

- escape performance
- motor activity
- Buprenorphine**, 215
  - drug physical dependence
  - drug reinforcement
  - drug self-administration
  - Rhesus monkey
- Bupropion**, 743
  - amphetamine
  - methylphenidate
  - minimal brain dysfunction
  - punished responding
- C57BL/6J mice**
  - ethanol metabolism, 495
  - locomotor activity, 723
  - phenobarbital, 723
  - rate dependency, 723
- Cadaverine**, 119
  - dopamine release inhibition
  - monopropionyl cadaverine
- Caffeine**
  - aminophylline, 157
  - reactivity, 875
  - stimulants, 875
  - stimulus control, 157
  - tactile startle, 875
- Calcium**, 975
  - antidepressants
  - imipramine
  - phospholipase A
  - platelets, human
  - receptor characterization
  - tricyclics
- Capacitance transducer**, 627
  - amphetamine-behavior assessment
  - spectral analysis
- Carbachol**
  - aggression, 747
  - caudate nucleus, 687
  - cholinergic stimulation, 747
  - conditioned avoidance, 537
  - conditioned pole jump response, 537
  - dopamine, 687
  - dopaminergic-cholinergic interaction, 687
  - globus pallidus, 687
  - irritability, 747
  - lateral hypothalamus, 747
  - muricide, 747
  - muscarinic receptors, 537
  - rotational behavior, 687
  - substantia nigra, 687
- Cat**
  - dopamine, 711
  - grooming, 865
  - hallucinogens, 865
  - limb flicking, 711, 865
  - lisuride, 711, 865
  - LSD, 711, 865
  - N-methylscopolamine, 865
  - pilocarpine, 865
  - serotonin, 711
  - yawning, 711
- Catalepsy**
  - activity, 545
  - AMPA, 545
  - body temperature, 545
  - dopamine, 243
  - locomotor activity, 243
  - nucleus accumbens, 243
  - seizures, 545
  - squirrel monkey, 243
- Catatonia/catalepsy**, 93
  - analgesia
  - convulsions, drug-induced
  - convulsions, electroshock-induced
  - postictal EEG depression
  - postictal immobility
- Catecholamine concentration and turnover**, 173
  - Animex motimeter
  - circadian rhythm
  - motor activity
  - strain differences
- Catecholamines**, 197
  - p*-chloroamphetamine
  - ejaculation
  - 5-hydroxytryptamine levels
  - hypothermia
  - irritability
  - salivation
  - thermoregulation
- Caudal reticular formation**, 501
  - analgesia
  - cyclic nucleotides
  - phosphodiesterase inhibitors
- Caudate nucleus**
  - atropine, 633
  - carbachol, 687
  - cholinergic inhibition, 633
  - dopamine, 687
  - dopaminergic-cholinergic interaction, 687
  - learning and retention, 633
  - memory, 633
  - oxotremorine, 687
  - passive avoidance, 633
  - rotational behavior, 687
- Cellular dehydration**, 263
  - angiotensin II
  - body temperature
  - conditioned taste aversion
  - drinking
  - hypovolemia
  - prostaglandins
  - water deprivation
- Central gray**, 37
  - lateral hypothalamus
  - morphine
  - self-stimulation
- Central nervous system**, 21
  - arecoline
  - drug discrimination
  - hippocampus
  - nicotine
  - reticular formation
- Central reward sites**, 131
  - naltrexone
  - opiate blockade
- Chick**
  - apomorphine, 895
  - dopaminergic mechanisms, 895
  - embryo, 773
  - fenfluramine, 895
  - morphine, 895
  - morphine tolerance, 773
  - quipazine, 895
  - serotonergic model, 895
  - tonic immobility, 895
- Chick embryo**
  - morphine tolerance, 773
- Chicken**, 739
  - alpha-adrenergic antagonists
  - animal hypnosis
  - phentolamine
  - prazosin
  - tonic immobility
  - yohimbine
- Chlordiazepoxide**
  - alcohol withdrawal, 185
  - eating, 577

- ethanol liquid diet, 185
- handling, 577
- open field test, 577
- p*-Chloroamphetamine
  - body weight, 297
  - catecholamines, 197
  - defecation, 297
  - ejaculation, 197
  - 5-hydroxytryptamine levels, 197
  - hypothermia, 197
  - irritability, 197
  - salivation, 197
  - thermoregulation, 197
  - urination, 297
- (-)-*threo*-Chlorocitric acid, 311
  - anorexia
  - gastric emptying decrease
- Chlorpromazine
  - anticipatory responding, 43
  - brain-stimulation reward, 903
  - enkephalin, 903
  - escape, 43
  - fixed-time schedule, 43
  - naloxone, 903
  - restraint, 43
  - schizophrenia, 903
- Choline acetyltransferase activity, 517
  - acetylcholinesterase activity
  - muricide
  - olfactory bulbectomy
  - scopolamine
- Cholinergic drugs, 537
  - atropine
  - carbachol
  - conditioned avoidance
  - conditioned pole jump response
  - muscarinic receptors
  - nicotine
  - oxotremorine
  - physostigmine
- Cholinergic inhibition, 633
  - atropine
  - caudate nucleus
  - learning and retention
  - memory
  - passive avoidance
- Cholinergic neurotransmitter system, 285
  - deanol
  - "defense reaction" syndrome
  - drug interaction
  - hemicholinium-3
- Cholinergic stimulation, 747
  - aggression
  - carbachol
  - irritability
  - lateral hypothalamus
  - muricide
- Chronic amphetamine, 161
  - osmotic minipumps
  - sensitization
  - stereotypy
  - tolerance
- Chronic amphetamine treatment, 399
  - dopaminergic function
  - tolerance, reverse tolerance and behavioral effects
- Chronic intracranial implants
  - fluoride and appliance dislodgment, 663
- Chronic iprindole, 951
  - cerebellum
  - cerebral cortex
  - dopamine
  - mesencephalon
  - monoamine oxidase inhibition
  - norepinephrine
  - serotonin
- Circadian rhythm
  - Animex motimeter, 173
  - catecholamine concentration and turnover, 173
  - DSIP, 717, 969
  - immunoreactivity, 969
  - locomotor activity, 717
  - motor activity, 173
  - phenobarbital, 235
  - phenytoin, 235
  - phosphorylation, 717
  - plasma corticosterone levels, 235
  - protein binding, 969
  - radioimmunoassay, 969
  - strain differences, 173
  - stress, 235
- Clonidine, 767
  - bar press
  - nose poke
  - self-stimulation
- Clorgyline
  - d-amphetamine, 75
  - deprenil, 75
  - l-dopa, 75
  - <sup>3</sup>H-dopamine release, 75
  - <sup>3</sup>H-dopamine uptake, 75
  - eating, 179
  - lesions, 6-OHDA, 75
  - locomotor activity, 179
  - Parkinsonism, 75
  - satiety, 179
  - sensorimotor performance, 179
  - serotonin, 179
  - substantia nigra, 75
- Clozapine, 415
  - fixed interval
  - schedule-controlled behavior
  - shock
  - squirrel monkey
  - stimulus-shock termination
- Coca, 907
  - cocaine
  - stimulus properties of drugs
- Cocaine
  - abuse liability, 49
  - aversive stimuli, 71
  - behavioral effects, 559
  - body weight, 485
  - coca, 907
  - drug-induced convulsions, 793
  - drug self-administration, 141
  - food deprivation, 141
  - gustatory avoidance conditioning, 71
  - kindling, 793
  - lidocaine, 793
  - olfactory bulb, 793
  - Pavlovian conditioning, 559
  - pentylene-tetrazol, 793
  - procaine, 49
  - reinforcing efficacy, 49
  - Rhesus monkey, 49, 141
  - schedule, 485
  - self-administration, 485
  - sensitization, 559
  - stimulus properties of drugs, 907
- Cockroach, 489
  - amnesia
  - learning and retention
  - protein synthesis inhibition
- Colchicine, 289
  - active avoidance
  - anisomycin
  - axoplasmic transport inhibition
  - memory
  - passive avoidance
  - podophyllotoxin

- protein synthesis inhibition
- vinblastine
- Concurrent schedules, 539
  - drinking
  - ethanol
  - reinforcement
- Conditioned avoidance, 537
  - cholinergic drugs
  - muscarinic receptors
  - pole jump response
- Conditioned defensive burying, 619
  - animal model
  - anxiety
  - anxiolytic drugs
- Conditioned pole jump response, 537
  - cholinergic drugs
  - muscarinic receptors
- Conditioned taste aversion
  - analgesia, 755
  - angiotensin II, 263
  - atropine, 827
  - body temperature, 263
  - cellular dehydration, 263
  - drinking, 263
  - heroin, 755
  - hypovolemia, 263
  - mecamylamine, 827
  - morphine, 651, 755
  - periaqueductal gray lesions, 651
  - physostigmine, 827
  - prostaglandins, 263
  - water deprivation, 263
- Conditioned taste preference, 915
  - brain-stimulation reward
  - dopamine receptor antagonism
  - pimozide
  - self-stimulation
- Conditioning, 463
  - ethanol-Metrecal
  - liquid diet
- Conflict behavior, 115
  - antianxiety drugs
  - diazepam
  - meprobamate
  - naloxone
  - opioid peptides
- Convulsions, drug-induced, 93
  - analgesia
  - catatonia/catalepsy
  - convulsions, electroshock-induced
  - postictal EEG depression
  - postictal immobility
- Convulsions, electroshock-induced, 93
  - analgesia
  - catatonia/catalepsy
  - convulsions, drug-induced
  - postictal EEG depression
  - postictal immobility
- Corpus striatum, 705
  - dopamine
  - L-fucose
  - glycoprotein synthesis
  - postnatal brain development
- Corticosterone, 761
  - adrenalectomy
  - estrogen-induced lordosis
  - ovariectomy
  - sexual behavior, female
- Cross adaptation, 377
  - multidimensional scaling
  - sweetness perception receptor sites
- Cross-tolerance, 471
  - ethanol
  - phenobarbital
  - polydipsia
- Cyclic nucleotides, 501
  - analgesia
  - caudal reticular formation
- Cycloheximide, 489
  - learning and retention
  - protein synthesis inhibition
- Cyproterone acetate, 691
  - 5-hydroxyindoleacetic acid
  - 5-hydroxytryptophan
  - plasma testosterone levels
  - shock-induced aggression
- Data acquisition, 135
  - behavior monitoring
  - microcomputerized protocol timer
- DBA/2J mice
  - ethanol metabolism, 495
- Deanol, 285
  - cholinergic neurotransmitter system
  - "defense reaction" syndrome
  - drug interaction
  - hemicholinium-3
- Defecation, 297
  - body weight
  - p-chloroamphetamine
  - urination
- "Defense reaction" syndrome, 285
  - cholinergic neurotransmitter system
  - deanol
  - drug interaction
  - hemicholinium-3
- Delta-Sleep-Inducing Peptide (DSIP), 717
  - circadian rhythm
  - locomotor activity
  - phosphorylation
- Deprenil, 75
  - d-amphetamine
  - clorgyline
  - l-dopa
  - <sup>3</sup>H-dopamine release
  - <sup>3</sup>H-dopamine uptake
  - lesions, 6-OHDA
  - Parkinsonism
  - substantia nigra
- Desmethylimipramine, 443
  - escape performance
  - motor activity
- Diabetes insipidus, 109
  - Brattleboro rat
  - drinking
  - naloxone
  - water deprivation
- Diazepam
  - antianxiety drugs, 115
  - conflict behavior, 115
  - eating, 577
  - handling, 577
  - meprobamate, 115
  - naloxone, 115
  - open field test, 577
  - opioid peptides, 115
- Diazepam binding, 965
  - endogenous inhibitor
  - GABA binding
- Diet palatability
  - dietary obesity, 89
  - eating, 15, 89
  - hyperphagia, 89
  - naltrexone, 89
  - norepinephrine-induced feeding, 15
  - ventromedial hypothalamic hyperphagia, 15
- Dietary obesity, 89
  - diet palatability
  - eating
  - hyperphagia
  - naltrexone

- Discrimination learning, 463
  - ethanol-Metrecal
  - liquid diet
- Discriminative performance, 371
  - depressant drugs
  - stimulant drugs
- Dissection time and leu-enkephalin binding, 849
  - endorphins
  - method of sacrifice and leu-enkephalin binding
  - opiate binding
  - opiate receptors
- Distractability, 81
  - activity levels
  - exploration
  - lithium chloride
  - selective attention
- DOM, 659
  - hallucinogens and operant responding
  - 5-hydroxytryptamine
  - metergoline
  - quipazine
- l-Dopa, 75
  - d-amphetamine
  - clorgyline
  - deprenil
  - <sup>3</sup>H-dopamine release
  - <sup>3</sup>H-dopamine uptake
  - lesions, 6-OHDA
  - Parkinsonism
  - substantia nigra
- Dopamine
  - amnesia, 911
  - carbachol, 687
  - cat, 711
  - catalepsy, 243
  - caudate nucleus, 687
  - corpus striatum, 705
  - dopaminergic-cholinergic interaction, 687
  - globus pallidus, 687
  - glycoprotein synthesis, 705
  - guanethidine, 911
  - hippocampus, 705
  - L-fucose, 705
  - limb flicking, 711
  - lisuride, 711
  - locomotor activity, 243
  - LSD, 711
  - morphine-induced feeding, 555
  - norepinephrine, 555
  - nucleus accumbens, 243
  - oxotremorine, 687
  - phentolamine, 555
  - postnatal brain development, 705
  - reserpine, 911
  - rotational behavior, 687
  - serotonin, 711
  - squirrel monkey, 243
  - substantia nigra, 687
  - syrosingopine, 911
  - ventromedial hypothalamus, 555
  - yawning, 711
- Dopamine and reward, 609
  - pigeon
  - pimozide
  - reinforcement, fixed consecutive number
  - stimulus control
- Dopamine metabolites, 933
  - dopamine receptors
  - pergolide
  - quipazine
  - serum corticosterone
- Dopamine receptor antagonism, 915
  - brain-stimulation reward
  - conditioned taste preference
  - pimozide
  - self-stimulation
- Dopamine receptor blockade
  - reward, 435
- Dopamine receptors, 933
  - dopamine metabolites
  - pergolide
  - quipazine
  - serum corticosterone
- Dopamine release inhibition, 119
  - cadaverine
  - monopropionyl cadaverine
- <sup>3</sup>H-Dopamine release, 75
  - d-amphetamine
  - clorgyline
  - deprenil
  - l-dopa
  - <sup>3</sup>H-dopamine uptake
  - lesions, 6-OHDA
  - Parkinsonism
  - substantia nigra
- <sup>3</sup>H-Dopamine uptake, 75
  - d-amphetamine
  - clorgyline
  - deprenil
  - l-dopa
  - <sup>3</sup>H-dopamine release
  - lesions, 6-OHDA
  - Parkinsonism
  - substantia nigra
- Dopaminergic-cholinergic interaction, 687
  - caudate nucleus
  - globus pallidus
  - rotational behavior
  - substantia nigra
- Dopaminergic function, 405
  - chronic amphetamine administration
  - tolerance and reverse tolerance
- Dopaminergic mechanisms, 895
  - apomorphine
  - chick
  - fenfluramine
  - morphine
  - quipazine
  - serotonergic model
  - tonic immobility
- Dorsal periaqueductal gray
  - aversive brain stimulation, 351
- Dorsal raphe nucleus, 419
  - analgesia
  - brain stimulation
  - naltrexone
  - opiate mechanisms
- Dose-response curves
  - depressant drugs, 371
  - nonlinear regression, 987
  - open-field test, 987
  - stimulant drugs, 371
- Drinking
  - activity level, 7
  - angiotensin, 337, 563
  - angiotensin II, 263
  - anteroventral third ventricle, 563
  - behavior, 7
  - body temperature, 263
  - brain serotonin, 201
  - Brattleboro rat, 109
  - cellular dehydration, 263
  - concurrent schedules, 539
  - conditioned taste aversion, 263
  - diabetes insipidus, 109
  - eating, 201
  - endorphins, 257, 319
  - ethanol, 539
  - gastric fistulas, 319
  - hyperdipsia, 591

hypovolemia, 263  
 isoproterenol-induced thirst, 563  
 lateral hypothalamus, 257  
 lateral ventricles, 257  
 locomotion, 201  
 MIF-I and analogs, 921  
 morphine, 477  
 muricide, 201  
 naloxone, 109, 257, 319, 477, 921  
 opiate peptides, 591  
 opioid systems, 477  
 periventricular preoptic-hypothalamic lesions, 563  
 phencyclidine, 7  
 pimozone, 435  
 prostaglandins, 263  
 quinine, 435  
 reinforcement, 539  
 sensory-motor function, 7  
 sex differences, 921  
 stereospecific opiate agonists and antagonists, 591  
 taste aversion, 7  
 tryptophan, 201  
 vena cava ligation, 337  
 water deprivation, 109, 257, 263, 319

**Drug**  
 alcohol, 191, 207  
 alpha-methyl-*p*-tyrosine, 197  
 aminophylline, 157  
 amitriptyline, 125, 393  
 amphetamine, 161, 167, 351, 371, 393, 399, 505, 641, 673, 701, 743, 807, 859  
 d-amphetamine, 75, 157, 357  
 anisomycin, 289  
 apomorphine, 149, 521, 701, 711, 895  
 arachidonic acid, 657  
 arecoline, 21  
 atropine, 21, 537, 633, 827  
 beta-antagonists, 597  
 benzodiazepines, 605, 681  
 bicuculline, 567  
 bromocriptine, 443  
 buprenorphine, 215  
 bupropion, 393, 743  
 butriptyline, 695  
 cadaverine, 119  
 caffeine, 157, 323, 875  
 carbachol, 537, 687, 747  
 chlordiazepoxide, 185, 351, 577, 605, 619, 695, 743  
 chlorimipramine, 197  
*p*-chloroamphetamine, 197, 297  
 (–)-*threo*-chlorocitric acid, 303  
*p*-chlorophenylalanine, 197, 363  
 chlorpromazine, 43, 619, 695, 903  
 clonazepam, 695  
 clonidine, 197, 767  
 clorgyline, 75, 179, 695  
 clozapine, 415  
 coca, 907  
 cocaine, 49, 71, 141, 425, 485, 559, 793, 907  
 colchicine, 289  
 cycloheximide, 489  
 cyproheptadine, 351  
 cyproterone acetate, 691  
 deanol, 285  
 deprenil, 75  
 desmethylimipramine, 443  
 diazepam, 115, 577, 605, 619, 695, 965  
 diethylpropion, 311  
 DOM, 659  
 l-dopa, 75  
 dopamine, 243, 405, 555, 609, 705, 711, 951  
 doxepin, 393  
 ethanol, 55, 101, 185, 207, 471, 495, 539, 551, 577, 651, 819, 871, 879, 945  
 etiracetam, 247  
 fenfluramine, 371, 651, 859, 895  
 FK 33-824, 729  
 fluoxetine, 125  
 flurazepam, 605, 695  
 guanethidine, 911  
 haloperidol, 61, 327, 393, 711, 767  
 hemicholinium-3, 285  
 heroin, 755  
 (–)-*threo*-hydroxycitric acid, 303  
 8-hydroxy-2-(di-*n*-propylamino)tetralin, 785  
 6-hydroxydopamine, 61, 167, 443  
 5-hydroxyindoleacetic acid, 691  
 5-hydroxytryptamine, 659  
 5-hydroxytryptophan, 363, 691, 871  
 imipramine, 125, 393, 743, 975  
 iprindole, 125, 951  
 isoproterenol, 563  
 ketamine, 145  
 lead, 641  
 lead acetate, 505  
 lidocaine, 425, 793  
 lisuride, 711, 865  
 lithium, 651  
 lithium chloride, 81  
 LSD, 711, 865  
 lumicolchicine, 289  
 mazindol, 311  
 mecamylamine, 21, 827  
 meprobamate, 115, 695  
 metergoline, 659  
 methadone, 887  
 methamphetamine, 521, 925  
 methocarbamol, 767  
 8-methoxy-2-(di-*n*-propylamino)tetralin, 785  
 methylphenidate, 743  
 N-methylscopolamine, 865  
 methysergide, 125, 351  
 metrazol, 93, 681  
 mianserin, 125, 393  
 morphine, 37, 109, 119, 167, 425, 477, 555, 571, 637, 651, 677, 729, 755, 773, 895  
 nadolol, 597  
 naloxone, 109, 115, 257, 319, 477, 513, 583, 681, 729, 887, 903, 921  
 naltrexone, 89, 109, 131, 419, 677  
 nicotine, 21, 371, 537, 587  
 norepinephrine, 15, 555, 951  
 oxotremorine, 271, 537, 687  
 parachlorophenylalanine, 197, 363  
 pentobarbital, 145, 207, 351, 371, 505, 577, 583, 619, 767, 799, 807  
 pentylenetetrazol, 533, 793  
 pergolide, 933  
 phencyclidine, 7, 145, 357, 807, 813  
 phenobarbital, 235, 471, 723, 743  
 phentolamine, 555, 739  
 phenylethylamine, 505  
 phenylpiperidine, 65  
 phenytoin, 235  
 phospholipase A, 975  
 physostigmine, 537, 827  
 picrotoxin, 93, 681  
 pilocarpine, 865  
 pimozone, 227, 435, 609, 655, 915  
 piracetam, 247  
 pizotyline, 157  
 podophyllotoxin, 289  
 prazosin, 739  
 procaine, 49, 425  
 puromycin, 489  
 quinine, 435  
 quipazine, 149, 659, 895, 933, 937  
 R05-4864, 695  
 reserpine, 779, 911  
 Ro 4-4602, 871  
 scopolamine, 389, 517

- serotonin, 711
- serotonin creatinine sulfate, 179
- sodium valproate, 681
- sotalol, 597
- spiperone, 157
- syrosingopine, 911
- $\Delta^9$ -tetrahydrocannabinol, 281, 779
- timolol, 597
- tranylcypromine, 393
- tryptophan, 201
- vinblastine, 289
- Drug discrimination
  - arecoline, 21
  - caffeine, 323
  - central nervous system, 21
  - hippocampus, 21
  - nicotine, 21
  - reticular formation, 21
- Drug-induced convulsions, 793
  - cocaine
  - kindling
  - lidocaine
  - olfactory bulb
  - pentylentetrazol
- Drug-induced stereotyped behavior, 701
  - amphetamine
  - apomorphine
  - avian behavior
  - pigeon
- Drug interaction
  - d-amphetamine, 357
  - cholinergic neurotransmitter system, 285
  - deanol, 285
  - "defense reaction" syndrome, 285
  - hemicholinium-3, 285
  - operant behavior, 357
  - phencyclidine, 357
- Drug physical dependence, 215
  - buprenorphine
  - drug reinforcement
  - drug self-administration
  - Rhesus monkey
- Drug reinforcement, 215
  - buprenorphine
  - drug physical dependence
  - drug self-administration
  - Rhesus monkey
- Drug self-administration
  - buprenorphine, 215
  - cocaine, 141
  - drug physical dependence, 215
  - drug reinforcement, 215
  - ethanol dependence, 101
  - food deprivation, 141
  - Rhesus monkey, 141, 215
  - withdrawal, 101
- DSIP
  - brain electrical activity, 845
  - circadian rhythm, 969
  - endorphin, 845
  - enkephalin, 845
  - immunoreactivity, 969
  - MSH, 845
  - opiates, 845
  - protein binding, 969
  - radioimmunoassay, 969
- DSIP peptides, 955
  - blood-brain barrier
  - radioimmunoassay
- Eating
  - amphetamine, 859
  - anorexia, 859
  - anxiolytic drugs, 577
  - brain serotonin, 201
  - clorgyline, 179
  - diet palatability, 15, 89
  - dietary obesity, 89
  - dopamine, 555
  - drinking, 201
  - ethanol-Metrecal, 455
  - fenfluramine, 859
  - handling, 577
  - hyperphagia, 89, 591
  - liquid diet, 455
  - locomotor activity, 179, 201
  - morphine, 477
  - morphine-induced feeding, 555
  - muricide, 201
  - naloxone, 477
  - naltrexone, 89
  - norepinephrine, 555
  - norepinephrine-induced feeding, 15
  - open field test, 577
  - opiate peptides, 591
  - opioid systems, 477
  - phentolamine, 555
  - prostaglandins, 735
  - satiety, 179
  - sensorimotor performance, 179
  - serotonin, 179
  - stereospecific opiate agonists and antagonists, 591
  - stress, 735
  - tail pinch, 735
  - tryptophan, 201
  - ventromedial hypothalamic hyperphagia, 15
- Ectostriatal seizures
  - D-glutamine, 367
- Ejaculation, 197
  - catecholamines
  - p*-chloroamphetamine
  - 5-hydroxytryptamine levels
  - hypothermia
  - irritability
  - salivation
  - thermoregulation
- Electrical brain stimulation, 227
  - fixed-interval behavior
  - food
  - neuroleptics
  - pimozide
  - reward and reward omission
- Electrical stimulation
  - epilepsy, 363
- Emotionality, 883
  - melatonin
  - open field
- Endocrine responsivity, 281
  - exteroceptive stimuli
  - hypothalamic-pituitary-gonadal axis
  - luteinizing hormone releasing factor
  - pheromones
  - social behavior, mice
  - testosterone
  - $\Delta^9$ -tetrahydrocannabinol
- Endogenous inhibitor, 965
  - diazepam binding
  - GABA binding
- Endogenous opiates, 853
  - leu-enkephalin binding
  - opiate receptors
  - stress-induced analgesia
- Endorphin
  - brain electrical activity, 845
  - dissection time and leu-enkephalin binding, 849
  - drinking, 257, 319
  - DSIP, 845
  - enkephalin, 845
  - footshock, 27
  - gastric fistulas, 319



- inbred mice, 513
- lateral hypothalamus, 257
- lateral ventricles, 257
- $\beta$ -lipotropin fragments, 27
- MSH, 845
- method of sacrifice and leu-enkephalin binding, 849
- MSH, 845
- naloxone, 257, 319, 513
- opiate binding, 849
- opiate receptors, 849
- opiates, 845
- shock-induced aggression, 513
- structure-activity relationships, 27
- water deprivation, 257, 319
- $\beta$ -Endorphin, 605
  - ACTH and excessive grooming
  - benzodiazepines
- Enkephalin
  - brain electrical activity, 845
  - brain-stimulation reward, 903
  - chlorpromazine, 903
  - DSIP, 845
  - endorphin, 845
  - MSH, 845
  - naloxone, 903
  - opiates, 845
  - schizophrenia, 903
- Leu-Enkephalin binding
  - dissection time, 849
  - endogenous opiates, 853
  - endorphins, 849
  - method of sacrifice, 849
  - opiate binding, 849, 853
  - opiate receptors, 849
  - stress-induced analgesia, 853
- Epilepsy
  - electrical stimulation, 363
- Escape
  - anticipatory responding, 43
  - chlorpromazine, 43
  - ethanol sensitivity, 33
  - fixed-time schedule, 43
  - pharmacogenetics, 33
  - restraint, 43
  - sex differences, 33
  - task dependency, 33
- Escape performance, 443
  - bromocriptine
  - desmethylinipramine
  - 6-hydroxydopamine
- Estrogen-induced lordosis, 761
  - adrenalectomy
  - corticosterone
  - ovariectomy
  - sexual behavior, female
- Ethanol
  - activity level, 819
  - aldosterone, 879
  - body temperature, 551
  - concurrent schedules, 539
  - cross-tolerance, 471
  - drinking, 539
  - eating, 577
  - food deprivation, 551
  - genetics, 945
  - handling, 577
  - hyperglycemia, 551
  - hypoglycemia, 551
  - hypothalamic tyrosine hydroxylase activity, 945
  - intra-gastric infusion, 495
  - liquid diet, 455
  - metabolism, 495
  - open field test, 577
  - phenobarbital, 471
  - polydipsia, 471
  - reinforcement, 539
  - renin, 879
  - sodium balance, 879
  - starvation, 551
  - wheel-running, 819
- Ethanol dependence
  - drug self-administration, 101
  - ethanol liquid diet, 55
  - sex differences, 55
  - withdrawal, 55, 101
- Ethanol intake, 871
  - brain serotonin
  - 5-hydroxytryptophan
  - Ro 4-4602
- Ethanol liquid diet
  - alcohol withdrawal, 185
  - chloridiazepoxide, 185
  - ethanol dependence, 55
  - sex differences, 55
  - withdrawal, 55
- Ethanol preferences, 207
  - alcohol consumption, female rats
  - alcohol consumption, inbred mice
  - pentobarbital
- Ethanol sensitivity, 33
  - escape
  - pharmacogenetics
  - sex differences
  - task dependency
- Etiracetam, 247
  - acquisition
  - extinction
  - open field
  - passive avoidance
  - piracetam
  - retention
- Exploration
  - activity levels, 81
  - animal model, 695
  - antidepressants, 695
  - anxiolytics, 695
  - benzodiazepines and behavior, 695
  - distractability, 81
  - lithium chloride, 81
  - locomotion, 695
  - neuroleptics, 695
  - sedation, 695
  - selective attention, 81
- Exteroceptive stimuli, 281
  - endocrine responsivity
  - hypothalamic-pituitary-gonadal axis
  - luteinizing hormone releasing factor
  - pheromones
  - social behavior, mice
  - testosterone
  - $\Delta^9$ -tetrahydrocannabinol, 281
- Extinction
  - acquisition, 247
  - etiracetam, 247
  - haloperidol, 327
  - open field, 247
  - operant response duration, 327
  - passive avoidance, 247
  - piracetam, 247
  - retention, 247
- Fenfluramine
  - amphetamine, 859
  - anorexia, 859
  - apomorphine, 895
  - chick, 895
  - dopaminergic mechanisms, 895
  - eating, 859
  - morphine, 895
  - quipazine, 895

- serotonergic model, 895
- tonic immobility, 895
- Fixed interval
  - amphetamine, 807
  - clozapine, 415
  - fixed ratio, 807
  - lever press, 807
  - multiple schedule, 807
  - pentobarbital, 807
  - phencyclidine, 807
  - schedule-controlled behavior, 415
  - shock, 415
  - squirrel monkey, 415
  - stimulus-shock termination, 415
- Fixed-interval behavior, 227
  - electrical brain stimulation
  - food
  - neuroleptics
  - pimozide
  - reward and reward omission
- Fixed ratio, 807
  - amphetamine
  - fixed interval
  - lever press
  - multiple schedule
  - pentobarbital
  - phencyclidine
- Fixed-time schedule, 43
  - anticipatory responding
  - chlorpromazine
  - escape
  - restraint
- FK 33-824, 729
  - inbred mice
  - locomotor activity
  - morphine
  - naloxone
- Fluoride
  - chronic intracranial implants, 663
- Food, 227
  - electrical brain stimulation
  - fixed-interval behavior
  - neuroleptics
  - pimozide
  - reward and reward omission
- Food deprivation
  - body temperature, 551
  - cocaine, 141
  - dietary lead and hyperactivity, 505
  - drug self-administration, 141
  - ethanol, 551
  - hyperglycemia, 551
  - hypoglycemia, 551
  - Rhesus monkey, 141
  - starvation, 551
- Footshock, 27
  - endorphins
  - $\beta$ -lipotropin fragments
  - structure-activity relationships
- Formalin test, 637
  - analgesia
  - behavioral tolerance
  - morphine
  - pain
  - tolerance
  - tonic pain
- L-Fucose, 705
  - corpus striatum
  - dopamine
  - glycoprotein synthesis
  - hippocampus
  - postnatal brain development
- GABA, 567
  - bicuculline
  - learned helplessness
- GABA binding, 965
  - diazepam binding
  - endogenous inhibitor
- Gastric emptying
  - (-)-*threo*-chlorocitric acid, 311
- Gastric fistulas, 319
  - drinking
  - endorphins
  - naloxone
  - water deprivation
- Genetics
  - ethanol, 945
  - hypothalamic tyrosine hydroxylase activity, 945
  - hypothermia, 271
  - muscarinic receptors, 271
  - open field, 271
  - oxotremorine, 271
- Globus pallidus, 687
  - carbachol
  - dopamine
  - dopaminergic-cholinergic interaction
  - oxotremorine
  - rotational behavior
- D-Glutamine, 367
  - ectostriatal seizures
  - retrograde amnesia
- Glycoprotein synthesis, 705
  - corpus striatum
  - dopamine
  - L-fucose
  - hippocampus
  - postnatal brain development
- Grooming, 865
  - cat
  - hallucinogens
  - limb flicks
  - lisuride
  - LSD
  - N-methylscopolamine
  - pilocarpine
- Grooming, excessive, 605
  - ACTH
  - benzodiazepines
  - $\beta$ -endorphin
- Guanethidine, 911
  - amnesia
  - brain catecholamine levels
- Gustatory avoidance conditioning, 71
  - aversive stimuli
  - cocaine
- Hallucinogens, 865
  - cat
  - grooming
  - limb flicks
  - lisuride
  - LSD
  - N-methylscopolamine
  - pilocarpine
- Hallucinogens and operant responding, 659
  - DOM
  - 5-hydroxytryptamine
  - metergoline
  - quipazine
- Haloperidol
  - bar press, 767
  - extinction, 327
  - 6-hydroxydopamine, 61
  - nigrostriatal dopaminergic system, 61
  - nose poke, 767
  - operant response duration, 327
  - prolactin-induced grooming, 61
  - self-stimulation, 767

Handling, 577  
   anxiolytic drugs  
   eating  
   open field test  
 Head-shakes, 937  
   quipazine  
   REM sleep  
   serotonergic activity  
   slow-wave sleep  
 Head twitches, 149  
   aggression  
   apomorphine  
   quipazine  
   REM sleep deprivation  
 Hemicholinium-3, 285  
   cholinergic neurotransmitter system  
   deanol  
   "defense reaction" syndrome  
   drug interaction  
 Heroin, 755  
   analgesia  
   conditioned taste aversion  
   morphine  
 Hippocampus  
   arecoline, 21  
   central nervous system, 21  
   dopamine, 705  
   drug discrimination, 21  
   L-fucose, 705  
   glycoprotein synthesis, 705  
   nicotine, 21  
   postnatal brain development, 705  
   reticular formation, 21  
 Hormone  
   ACTH, 605  
   aldosterone, 879  
   angiotensin, 337, 563  
   angiotensin II, 263  
   corticosterone, 235, 761, 933  
   desoxycorticosterone, 761  
   estrogen, 761  
   LH, 281  
   LHRH, 961  
   melatonin, 883  
   progesterone, 761  
   prolactin, 61  
   prostaglandin E<sub>2</sub>, 263, 657  
   prostaglandin F<sub>2a</sub>, 657  
   testosterone, 281, 691  
 Housing conditions  
   morphine self-administration, 571  
 Huntington's disease, 779  
   reserpine-induced hypokinesia  
    $\Delta^9$ -tetrahydrocannabinol  
 6-Hydroxydopamine  
   activity responses, 167  
   amphetamine, 167  
   brain catecholamines, 167  
   escape performance, 443  
   haloperidol, 61  
   morphine, 167  
   motor activity, 443  
   nigrostriatal dopaminergic system, 61  
   norepinephrine levels, 167  
   prolactin-induced grooming, 61  
 5-Hydroxyindoleacetic acid, 691  
   cyproterone acetate  
   plasma testosterone levels  
   shock-induced aggression  
 8-Hydroxy-2-(di-n-propylamino)tetrinalin, 785  
   5-hydroxytryptamine receptors  
   sexual behavior  
 5-Hydroxytryptamine  
   DOM, 659  
   hallucinogens and operant responding, 659  
   metergoline, 659  
   noradrenaline, 1  
   quipazine, 659  
   sodium depletion, 1  
   sodium load, 1  
 5-Hydroxytryptamine levels, 197  
   catecholamines  
   *p*-chloroamphetamine  
   ejaculation  
   hypothermia  
   irritability  
   salivation  
   thermoregulation  
 5-Hydroxytryptamine receptors, 785  
   8-hydroxy-2-(di-n-propylamino)tetrinalin  
   8-methoxy-2-(di-n-propylamino)tetrinalin  
   sexual behavior  
 5-Hydroxytryptophan  
   brain serotonin, 871  
   cyproterone acetate, 691  
   ethanol intake, 871  
   plasma testosterone levels, 691  
   Ro 4-4602, 871  
   shock-induced aggression, 691  
 Hyperactivity, 545  
   AMPA  
   body temperature  
   catalepsy  
   seizures  
   wet dog shakes  
 Hyperglycemia, 551  
   body temperature  
   ethanol and food deprivation  
   ethanol and starvation  
   hypoglycemia  
 Hyperphagia, 89  
   diet palatability  
   dietary obesity  
   eating  
   naltrexone  
 Hyperthermia, 545  
   activity  
   AMPA  
   catalepsy  
   seizures  
   wet dog shakes  
 Hypoactivity, 545  
   AMPA  
   body temperature  
   catalepsy  
   seizures  
   wet dog shakes  
 Hypoglycemia, 551  
   body temperature  
   ethanol and food deprivation  
   ethanol and starvation  
   hyperglycemia  
 Hypokinesia, 779  
   reserpine  
    $\Delta^9$ -tetrahydrocannabinol  
 Hypothalamic-pituitary-gonadal axis, 281  
   endocrine responsivity  
   exteroceptive stimuli  
   luteinizing hormone releasing factor  
   pheromones  
   social behavior, mice  
   testosterone  
    $\Delta^9$ -tetrahydrocannabinol  
 Hypothalamic tyrosine hydroxylase activity, 945  
   ethanol  
   genetics  
 Hypothermia  
   activity, 545  
   AMPA, 545  
   catalepsy, 545

- catecholamines, 197
- p*-chloroamphetamine, 197
- ejaculation, 197
- genetics, 271
- 5-hydroxytryptamine levels, 197
- irritability, 197
- muscarinic receptors, 271
- open field, 271
- oxotremorine, 271
- salivation, 197
- seizures, 545
- thermoregulation, 197
- wet dog shakes, 545
- Hypovolemia, 263
  - angiotensin II
  - body temperature
  - cellular dehydration
  - conditioned taste aversion
  - drinking
  - prostaglandins
  - water deprivation
- Imipramine
  - antidepressants, 975
  - calcium, 975
  - olfactory bulbectomy, 393
  - passive avoidance, 393
  - phospholipase A, 975
  - platelets, human, 975
  - receptor characterization, 975
  - tricyclics, 975
- Immunoreactivity, 969
  - circadian rhythm
  - DSIP
  - protein binding
  - radioimmunoassay
- Inbred mice
  - endorphins, 513
  - FK 33-824, 729
  - locomotor activity, 729
  - morphine, 729
  - naloxone, 513, 729
  - shock-induced aggression, 513
- Intracranial self-stimulation, 583
  - naloxone
  - pentobarbital
  - ventral tegmental area
- Intragastric infusion
  - ethanol metabolism, 495
- Irritability
  - aggression, 747
  - carbachol, 747
  - catecholamines, 197
  - p*-chloroamphetamine, 197
  - cholinergic stimulation, 747
  - ejaculation, 197
  - 5-hydroxytryptamine levels, 197
  - hypothermia, 197
  - lateral hypothalamus, 747
  - muricide, 747
  - salivation, 197
  - thermoregulation, 197
- Isoproterenol, 563
  - angiotensin
  - anteroventral third ventricle
  - drinking
  - periventricular preoptic-hypothalamic lesions
- Ketamine, 145
  - pentobarbital
  - phencyclidine
  - pigeon
  - punished and unpunished responding
- Kindling, 793
  - cocaine
  - drug-induced convulsions
  - lidocaine
  - olfactory bulb
  - pentylentetrazol
- Lateral hypothalamus
  - aggression, 747
  - carbachol, 747
  - central gray, 37
  - cholinergic stimulation, 747
  - drinking, 257
  - endorphins, 257
  - irritability, 747
  - lateral ventricles, 257
  - morphine, 37
  - muricide, 747
  - naloxone, 257
  - self-stimulation, 37
  - water deprivation, 257
- Lateral ventricles, 257
  - drinking
  - endorphins
  - lateral hypothalamus
  - naloxone
  - water deprivation
- Lead, 641
  - amphetamine
  - neonatal exposure and striatal dopamine
- Lead acetate, 505
  - amphetamine
  - food deprivation
  - hyperactivity
  - pentobarbital
  - phenylethylamine
  - starvation
- Learned helplessness, 567
  - bicuculline
  - GABA
- Learning, 655
  - pimozide
  - reward
- Learning and enhancement of drug effect, 925
  - ambulatory activity
  - methamphetamine
- Learning and retention
  - atropine, 633
  - caudate nucleus, 633
  - cholinergic inhibition, 633
  - cockroach, 489
  - cycloheximide, 489
  - memory, 633
  - passive avoidance, 633
  - protein synthesis inhibition, 489
  - puromycin, 489
- Lesions
  - angiotensin, 563
  - anteroventral third ventricle, 563
  - conditioned taste aversion, 651
  - drinking, 563
  - isoproterenol-induced thirst, 563
  - morphine, 651
  - muricide, 343
  - periaqueductal gray, 651
  - periventricular preoptic-hypothalamus, 563
  - raphe nuclei, 363
  - septum, 343
  - tryptophan, 343
- Lesions, 6-OHDA, 75
  - d-amphetamine
  - clorgyline
  - deprenil
  - l-dopa

- <sup>3</sup>H-dopamine release
- <sup>3</sup>H-dopamine uptake
- Parkinsonism
  - substantia nigra
- Lever press, 807
  - amphetamine
  - fixed interval
  - fixed ratio
  - multiple schedule
  - pentobarbital
  - phencyclidine
- LHRH analog, 961
  - lordosis
  - ovulation inhibition
  - sexual behavior
  - sexual receptivity
- Lidocaine, 793
  - cocaine
  - drug-induced convulsions
  - kindling
  - olfactory bulb
  - pentyletetrazol
- Limb flicking
  - cat, 711, 865
  - dopamine, 711
  - grooming, 865
  - hallucinogens, 865
  - lisuride, 711, 865
  - LSD, 711, 865
  - N-methylscopolamine, 865
  - pilocarpine, 865
  - serotonin, 711
  - yawning, 711
- Lipid synthesis
  - (-)-*threo*-chlorocitric acid, 311
- $\beta$ -Lipotropin fragments, 27
  - endorphins
  - footshock
  - structure-activity relationships
- Liquid diet, 455
  - ethanol
  - Metrecal
- Lisuride
  - cat, 711, 865
  - dopamine, 711
  - grooming, 865
  - hallucinogens, 865
  - limb flicking, 711, 865
  - LSD, 711, 865
  - N-methylscopolamine, 865
  - pilocarpine, 865
  - serotonin, 711
  - yawning, 711
- Lithium chloride, 81
  - activity levels
  - distractability
  - exploration
  - selective attention
- Liver, 449
  - mercury
  - selenium
- Location avoidance and aversive drug stimulus
  - scopolamine, 389
- Locomotion
  - animal models, 695
  - antidepressants, 695
  - anxiolytics, 695
  - benzodiazepines and behavior, 695
  - brain serotonin, 201
  - drinking, 201
  - eating, 201
  - exploration, 695
  - muricide, 201
  - neuroleptics, 695
  - sedation, 695
  - tryptophan, 201
- Locomotor activity
  - C57BL/6J mice, 723
  - catalepsy, 243
  - circadian rhythm, 717
  - clorgyline, 179
  - cocaine, 425
  - dopamine, 243
  - DSIP, 717
  - eating, 179
  - FK 33-824, 729
  - inbred mice, 729
  - lidocaine, 425
  - morphine, 425, 729
  - naloxone, 729
  - nucleus accumbens, 243
  - phenobarbital, 723
  - phosphorylation, 717
  - procaine, 425
  - rate dependency, 723
  - satiety, 179
  - sensorimotor performance, 179
  - serotonin, 179
  - squirrel monkey, 243
- Lordosis, 961
  - LHRH analog
  - ovulation inhibition
  - sexual behavior
  - sexual receptivity
- LSD
  - cat, 711, 865
  - dopamine, 711
  - grooming, 865
  - hallucinogens, 865
  - limb flicking, 711, 865
  - lisuride, 711, 865
  - N-methylscopolamine, 865
  - pilocarpine, 865
  - serotonin, 711
  - yawning, 711
- Lumbar epidural catheterization
  - long-term drug administration, 515
- Luteinizing hormone releasing factor, 281
  - endocrine responsivity
  - exteroceptive stimuli
  - hypothalamic-pituitary-gonadal axis
  - pheromones
  - social behavior, mice
  - testosterone
  - $\Delta^9$ -tetrahydrocannabinol
- Maze learning, 463
  - ethanol-Metrecal
  - liquid diet
- Mecamylamine
  - conditioned taste aversion, 827
- Melatonin, 883
  - emotionality
  - open field
- Memory
  - active avoidance, 289
  - anisomycin, 289
  - atropine, 633
  - axoplasmic transport inhibition, 289
  - caudate nucleus, 633
  - cholinergic inhibition, 633
  - colchicine, 289
  - learning and retention, 633
  - passive avoidance, 289, 633
  - podophyllotoxin, 289
  - protein synthesis inhibition, 289
  - vinblastine, 289
- Meproamate, 115
  - antianxiety drugs

- diazepam
- naloxone
- opioid peptides
- conflict behavior
- Mercury, 449
  - liver
  - proteinase digestion
  - selenium
- Metergoline, 659
  - DOM
  - hallucinogens and operant responding
  - 5-hydroxytryptamine
  - quipazine
- Methadone, 887
  - naloxone
  - opiates
  - perinatal exposure
  - withdrawal
- Methamphetamine
  - ambulatory activity, 925
  - apomorphine, 521
  - learning and enhancement of drug effect, 925
  - stereotyped licking and sniffing, 521
- Methocarbamol, 767
  - bar press
  - nose poke
  - self-stimulation
- Method
  - cross adaptation, 377
  - dose-response curves, 987
  - fluoride and chronic intracranial implants, 663
  - intra-gastric infusion, 495
  - lumbar epidural catheterization, 515
  - multidimensional scaling, 377
  - nonlinear regression, 987
  - open-field test, 987
  - radioimmunoassay, 955, 969
- Method of sacrifice and leu-enkephalin binding, 849
  - dissection time and leu-enkephalin binding
  - endorphins
  - opiate binding
  - opiate receptors
- 8-Methoxy-2-(di-n-propylamino)tetralin, 785
  - 5-hydroxytryptamine receptors
  - sexual behavior
- Methylphenidate, 743
  - amphetamine
  - bupropion
  - minimal brain dysfunction
  - punished responding
- N-Methylscopolamine, 865
  - cat
  - grooming
  - hallucinogens
  - limb flicks
  - lisuride
  - LSD
  - pilocarpine
- Metrecal
  - liquid diet, 455
- Mice, female, 191
  - alcohol and estrous cycle
  - alcohol sensitivity
  - ovariectomy
- Microcomputerized protocol timer, 135
  - behavior monitoring
  - data acquisition
- MIF-I and analogs
  - drinking, 921
  - naloxone, 921
  - reserpine-induced hypothermia, 983
  - sex differences, 921
- Minimal brain dysfunction, 743
  - amphetamine
  - bupropion
  - methylphenidate
  - punished responding
- Monoamine oxidase inhibition, 951
  - cerebellum
  - cerebral cortex
  - chronic iprindole
  - dopamine
  - mesencephalon
  - norepinephrine
  - serotonin
- Monopropionyl cadaverine, 119
  - cadaverine
  - dopamine release inhibition
- Morphine
  - activity responses, 167
  - amphetamine, 167
  - analgesia, 637, 755
  - apomorphine, 895
  - behavioral tolerance, 637
  - brain catecholamines, 167
  - central gray, 37
  - chick, 895
  - chick embryo, 773
  - conditioned taste aversion, 651, 755
  - dopaminergic mechanisms, 895
  - drinking, 477
  - eating, 477
  - fenfluramine, 895
  - FK 33-824, 729
  - Formalin test, 637
  - heroin, 755
  - housing conditions, 571
  - 6-hydroxydopamine, 167
  - inbred mice, 729
  - lateral hypothalamus, 37
  - locomotor activity, 729
  - naloxone, 729
  - norepinephrine levels, 167
  - opioid systems, 477
  - pain, 637
  - periaqueductal gray lesions, 651
  - quipazine, 895
  - self-stimulation, 37, 571
  - serotonergic model, 895
  - tolerance, 637, 773
  - tonic immobility, 895
  - tonic pain, 637
- Morphine-induced feeding, 555
  - dopamine
  - norepinephrine
  - phentolamine
  - ventromedial hypothalamus
- Motor activity
  - Animex motimeter, 173
  - bromocriptine, 443
  - catecholamine concentration and turnover, 173
  - circadian rhythm, 173
  - desmethylinipramine, 443
  - 6-hydroxydopamine, 443
  - strain differences, 173
- MSH, 845
  - brain electrical activity
  - DSIP
  - endorphin
  - enkephalin
  - opiates
- Multidimensional scaling, 377
  - cross adaptation
  - sweetness perception receptor sites
- Multiple schedule, 807
  - amphetamine
  - fixed interval
  - fixed ratio
  - lever press
  - pentobarbital

- phencyclidine
- Muricide
  - acetylcholinesterase activity, 517
  - aggression, 747
  - brain serotonin, 201
  - carbachol, 747
  - choline acetyltransferase activity, 517
  - cholinergic stimulation, 747
  - drinking, 201
  - eating, 201
  - irritability, 747
  - lateral hypothalamus, 747
  - locomotion, 201
  - olfactory bulbectomy, 517
  - scopolamine, 517
  - septal lesions, 343
  - tryptophan, 201, 343
- Muscarinic receptors
  - cholinergic drugs, 537
  - conditioned avoidance, 537
  - conditioned pole jump response, 537
  - genetics, 271
  - hypothermia, 271
  - open field, 271
  - oxotremorine, 271
- Nadolol, 597
  - $\beta$ -antagonists and amnesia
  - passive avoidance learning
- Naloxone
  - antianxiety drugs, 115
  - brain-stimulation reward, 903
  - Brattleboro rat, 109
  - chlorpromazine, 903
  - conflict behavior, 115
  - diabetes insipidus, 109
  - diazepam, 115
  - drinking, 109, 257, 319, 477, 921
  - eating, 477
  - endorphins, 257, 319, 513
  - enkephalin, 903
  - FK 33-824, 729
  - gastric fistulas, 319
  - inbred mice, 513, 729
  - intracranial self-stimulation, 583
  - lateral hypothalamus, 257
  - lateral ventricles, 257
  - locomotor activity, 729
  - meprobamate, 115
  - methadone, 887
  - MIF-I and analogs, 921
  - morphine, 729
  - opiates, 887
  - opioid peptides, 115
  - opioid systems, 477
  - pentobarbital, 583
  - perinatal exposure, 887
  - schizophrenia, 903
  - sex differences, 921
  - shock-induced aggression, 513
  - ventral tegmental area, 583
  - water deprivation, 109, 257, 319
  - withdrawal, 887
- Naltrexone
  - analgesia blockade, 419
  - behavioral tolerance, 677
  - central reward sites, 131
  - diet palatability, 89
  - dietary obesity, 89
  - dorsal raphe nucleus, 419
  - eating, 89
  - hyperphagia, 89
  - opiate analgesia, 677
  - opiate blockade, 131
- tail flick, 677
- Narcotic antagonists, 65
  - phenylpiperidine
  - pigeon
  - schedule-controlled responding
- Neuroleptics
  - animal model, 695
  - antidepressants, 695
  - anxiolytics, 695
  - benzodiazepines and behavior, 695
  - electrical brain stimulation, 227
  - exploration, 695
  - fixed-interval behavior, 227
  - food, 227
  - locomotion, 695
  - pimozide, 227
  - reward and reward omission, 227
  - sedation, 695
- Nicotine
  - arecoline, 21
  - central nervous system, 21
  - conditioned avoidance, 537
  - conditioned pole jump response, 537
  - drug discrimination, 21
  - hippocampus, 21
  - muscarinic receptors, 537
  - reticular formation, 21
- Nicotine-induced depression, 587
  - brainstem auditory evoked response
  - serotonin
- Nigrostriatal dopaminergic system, 61
  - haloperidol
  - 6-hydroxydopamine
  - prolactin-induced grooming
- Nonlinear regression, 987
  - dose-response curves
  - open-field test
- Noradrenaline, 1
  - 5-hydroxytryptamine
  - sodium depletion
  - sodium load
- Norepinephrine
  - amnesia, 911
  - dopamine, 555
  - guanethidine, 911
  - morphine-induced feeding, 555
  - phentolamine, 555
  - reserpine, 911
  - syrosingopine, 911
  - ventromedial hypothalamus, 555
- Norepinephrine-induced feeding, 15
  - diet palatability
  - eating
  - ventromedial hypothalamic hyperphagia
- Norepinephrine levels, 167
  - activity responses
  - amphetamine
  - brain catecholamines
  - 6-hydroxydopamine
  - morphine
- Nose poke, 767
  - bar press
  - clonidine
  - haloperidol
  - methocarbamol
  - pentobarbital
  - self-stimulation
- Nucleus accumbens, 243
  - catalepsy
  - dopamine
  - locomotor activity
  - squirrel monkey
- Nucleus reticularis pontis caudalis, 657
  - arachidonic acid
  - body temperature

- Olfactory bulb, 793
  - cocaine
  - drug-induced convulsions
  - kindling
  - lidocaine
  - pentylentetrazol
- Olfactory bulbectomy
  - acetylcholinesterase activity, 517
  - antidepressants, 393
  - choline acetyltransferase activity, 517
  - muricide, 517
  - passive avoidance, 393
  - scopolamine, 517
- Open field
  - acquisition, 247
  - emotionality, 883
  - etiracetam, 247
  - extinction, 247
  - genetics, 271
  - hypothermia, 271
  - melatonin, 883
  - muscarinic receptors, 271
  - oxotremorine, 271
  - passive avoidance, 247
  - piracetam, 247
  - retention, 247
- Open field activity
  - amphetamine, 505
  - cocaine, 425
  - dietary lead and hyperactivity, 505
  - food deprivation, 505
  - lidocaine, 425
  - morphine, 425
  - phenylethylamine, 505
  - procaine, 425
  - starvation, 505
- Open field test
  - anxiolytic drugs, 577
  - dose-response curves, 987
  - eating, 577
  - handling, 577
  - nonlinear regression, 987
- Operant behavior
  - d-amphetamine, 357
  - drug discrimination, 323
  - drug interaction, 357
  - phencyclidine, 357
- Operant responding and hallucinogens, 659
  - DOM
  - 5-hydroxytryptamine
  - metergoline
  - quipazine
- Operant response duration, 327
  - extinction
  - haloperidol
- Opiate analgesia, 677
  - behavioral tolerance
  - naltrexone
- Opiate binding, 849
  - dissection time and leu-enkephalin binding
  - endorphins
  - method of sacrifice and leu-enkephalin binding
  - opiate receptors
- Opiate blockade, 131
  - central reward sites
  - naltrexone
- Opiate peptides, 591
  - drinking
  - eating
  - hyperdipsia
  - hyperphagia
  - stereospecific opiate agonists and antagonists
- Opiate receptors
  - dissection time and leu-enkephalin binding, 849
  - endogenous opiates, 853
  - endorphins, 849
  - leu-enkephalin binding, 853
  - method of sacrifice and leu-enkephalin binding, 849
  - opiate binding, 849
  - stress-induced analgesia, 853
- Opiates
  - brain electrical activity, 845
  - DSIP, 845
  - endorphin, 845
  - enkephalin, 845
  - methadone, 887
  - MSH, 845
  - naloxone, 887
  - perinatal exposure, 887
  - withdrawal, 887
- Opioid peptides, 115
  - antianxiety drugs
  - conflict behavior
  - diazepam
  - meprobamate
  - naloxone
- Opioid systems, 477
  - drinking
  - eating
- Osmotic minipumps, 161
  - chronic amphetamine
  - sensitization
  - stereotypy
  - tolerance
- Ovariectomy
  - adrenalectomy, 761
  - alcohol and estrous cycle, 191
  - alcohol sensitivity, 191
  - corticosterone, 761
  - estrogen-induced lordosis, 761
  - mice, female, 191
  - sexual behavior, female, 761
- Ovulation inhibition, 961
  - LHRH analog
  - lordosis
  - sexual behavior
  - sexual receptivity
- Oxotremorine
  - caudate nucleus, 687
  - conditioned avoidance, 537
  - conditioned pole jump response, 537
  - dopamine, 687
  - dopaminergic-cholinergic interaction, 687
  - genetics, 271
  - globus pallidus, 687
  - hypothermia, 271
  - muscarinic receptors, 271, 537
  - open field, 271
  - rotational behavior, 687
  - substantia nigra, 687
- Pain, 637
  - analgesia
  - behavioral tolerance
  - Formalin test
  - morphine
  - tolerance
  - tonic pain
- Parkinsonism
  - d-amphetamine, 75
  - clorgyline, 75
  - deprenil, 75
  - l-dopa, 75
  - <sup>3</sup>H-dopamine release, 75
  - <sup>3</sup>H-dopamine uptake, 75
  - lesions, 6-OHDA, 75
  - reserpine-induced hypokinesia, 779
  - substantia nigra, 75
  - $\Delta^9$ -tetrahydrocannabinol, 779



- Passive avoidance
  - acquisition, 247
  - active avoidance, 289
  - anisomycin, 289
  - antidepressants, 393
  - axoplasmic transport inhibition, 289
  - colchicine, 289
  - etiracetam, 247
  - extinction, 247
  - memory, 289
  - olfactory bulbectomy, 393
  - open field, 247
  - piracetam, 247
  - podophyllotoxin, 289
  - protein synthesis inhibition, 289
  - retention, 247
  - vinblastine, 289
- Passive avoidance learning, 597
  - $\beta$ -antagonists and amnesia
  - nadolol
  - sotalol
  - timolol
- Passive avoidance learning, retention, 633
  - atropine
  - caudate nucleus
  - cholinergic inhibition
  - memory
- Pavlovian conditioning, 559
  - cocaine
  - sensitization
- Pentobarbital
  - alcohol consumption, female rats, 207
  - alcohol consumption, inbred mice, 207
  - amphetamine, 807
  - auditory threshold, 799
  - baboon, 799
  - bar press, 767
  - dietary lead and hyperactivity, 505
  - eating, 577
  - ethanol preferences, 207
  - fixed interval, 807
  - fixed ratio, 807
  - handling, 577
  - intracranial self-stimulation, 583
  - ketamine, 145
  - lever press, 807
  - multiple schedule, 807
  - naloxone, 583
  - nose poke, 767
  - open field test, 577
  - phencyclidine, 145, 807
  - pigeon, 145
  - primate, 799
  - punished and unpunished responding, 145
  - reaction time, 799
  - self-stimulation, 767
  - ventral tegmental area, 583
  - visual threshold, 799
- Pentylentetrazol, 793
  - cocaine
  - drug-induced convulsions
  - kindling
  - lidocaine
  - olfactory bulb
- Pentylentetrazol sensitization transfer, 533
  - amygdaloid kindling
  - seizures
- Peptide
  - Delta-Sleep-Inducing Peptide (DSIP), 717, 845, 955, 969
  - $\beta$ -endorphin, 27, 605, 845
  - $\gamma$ -endorphin, 27, 845
  - enkephalin, 903
  - Leu-enkephalin, 845, 849, 853
  - Met-enkephalin, 845
  - MIF-1, 919, 983
  - $\alpha$ -MSH, 845
  - opiates, 591, 845
  - Tyr-MIF-1, 921
  - tyrosine hydroxylase, 945
- Pergolide, 933
  - dopamine metabolites
  - dopamine receptors
  - quipazine
  - serum corticosterone
- Periaqueductal gray lesions, 651
  - conditioned taste aversion
  - morphine
- Perinatal exposure, 887
  - methadone
  - naloxone
  - opiates
  - withdrawal
- Periventricular preoptic-hypothalamus, 563
  - angiotensin
  - anteroventral third ventricle
  - drinking
  - isoproterenol-induced thirst
- Pharmacogenetics, 33
  - escape
  - ethanol sensitivity
  - sex differences
  - task dependency
- Phencyclidine
  - activity level, 7
  - amphetamine, 807
  - d-amphetamine, 357
  - behavior, 7
  - drinking, 7
  - drug interaction, 357
  - fixed interval, 807
  - fixed ratio, 807
  - ketamine, 145
  - lever press, 807
  - multiple schedule, 807
  - operant behavior, 357
  - pentobarbital, 145, 807
  - pigeon, 145
  - punished and unpunished responding, 145
  - sensory-motor function, 7
  - shock-induced aggression, 813
  - taste aversion, 7
- Phenobarbital
  - C57BL/6J mice, 723
  - circadian rhythms, 235
  - cross-tolerance, 471
  - ethanol, 471
  - locomotor activity, 723
  - phenytoin, 235
  - plasma corticosterone levels, 235
  - polydipsia, 471
  - rate dependency, 723
  - stress, 235
- Phentolamine
  - alpha-adrenergic antagonists, 739
  - animal hypnosis, 739
  - chicken, 739
  - dopamine, 555
  - morphine-induced feeding, 555
  - norepinephrine, 555
  - prazosin, 739
  - tonic immobility, 739
  - ventromedial hypothalamus, 555
  - yohimbine, 739
- Phenylethylamine
  - dietary lead and hyperactivity, 505
- Phenylpiperidine, 65
  - narcotic antagonists
  - pigeon
  - schedule-controlled responding
- Phenytoin, 235

- circadian rhythms
- phenobarbital
- plasma corticosterone levels
- stress
- Pheromones, 281**
  - endocrine responsivity
  - exteroceptive stimuli
  - hypothalamic-pituitary-gonadal axis
  - luteinizing hormone releasing factor
  - social behavior, mice
  - testosterone
  - $\Delta^9$ -tetrahydrocannabinol
- Phosphodiesterase inhibitors, 501**
  - analgesia
  - caudal reticular formation
- Phospholipase A, 975**
  - antidepressants
  - calcium
  - imipramine
  - platelets, human
  - receptor characterization
  - tricyclics
- Phosphorylation, 717**
  - circadian rhythm
  - DSIP
  - locomotor activity
- Physostigmine**
  - conditioned avoidance, 537
  - conditioned pole jump response, 537
  - conditioned taste aversion, 827
  - muscarinic receptors, 537
- Pigeon**
  - amphetamine, 701
  - apomorphine, 701
  - avian behavior, 701
  - dopamine and reward, 609
  - drug-induced stereotyped behavior, 701
  - ketamine, 145
  - narcotic antagonists, 65
  - pentobarbital, 145
  - phencyclidine, 145
  - phenylpiperidine, 65
  - pimozide, 609
  - punished and unpunished responding, 145
  - reinforcement, fixed consecutive number, 609
  - schedule-controlled responding, 65
  - stimulus control, 609
- Pilocarpine, 865**
  - cat
  - grooming
  - hallucinogens
  - limb flicks
  - lisuride
  - LSD
  - N-methylscopolamine
- Pimozide**
  - brain-stimulation reward, 915
  - conditioned taste preference, 915
  - dopamine and reward, 609
  - dopamine receptor antagonism, 915
  - drinking, 435
  - electrical brain stimulation, 227
  - fixed-interval behavior, 227
  - food, 227
  - learning, 655
  - neuroleptics, 227
  - pigeon, 609
  - reinforcement, fixed consecutive number, 609
  - reward, 655
  - reward and reward omission, 227
  - self-stimulation, 915
  - stimulus control, 609
- Piracetam, 247**
  - acquisition
  - etiracetam
- extinction
- open field
- passive avoidance
- retention
- Plasma corticosterone levels, 235**
  - circadian rhythms
  - phenobarbital
  - phenytoin
  - stress
- Plasma testosterone levels, 691**
  - cyproterone acetate
  - 5-hydroxyindoleacetic acid
  - 5-hydroxytryptophan
  - shock-induced aggression
- Platelets, human, 975**
  - antidepressants
  - calcium
  - imipramine
  - phospholipase A
  - receptor characterization
  - tricyclics
- Podophyllotoxin, 289**
  - active avoidance
  - anisomycin
  - axoplasmic transport inhibition
  - colchicine
  - memory
  - passive avoidance
  - protein synthesis inhibition
  - vinblastine
- Polydipsia, 471**
  - cross-tolerance
  - ethanol
  - phenobarbital
- Postictal EEG depression, 93**
  - analgesia
  - catatonia/catalepsy
  - convulsions, drug-induced
  - convulsions, electroshock-induced
  - postictal immobility
- Postictal immobility, 93**
  - analgesia
  - catatonia/catalepsy
  - convulsions, drug-induced
  - convulsions, electroshock-induced
  - postictal EEG depression
- Postnatal brain development, 705**
  - corpus striatum
  - dopamine
  - L-fucose
  - glycoprotein synthesis
  - hippocampus
- Postsynaptic effects, 125**
  - animal model, depression
  - antidepressants
  - presynaptic effects
  - serotonergic receptors
- Prazosin, 739**
  - alpha-adrenergic antagonists
  - animal hypnosis
  - chicken
  - phentolamine
  - tonic immobility
  - yohimbine
- Presynaptic effects, 125**
  - animal model, depression
  - antidepressants
  - postsynaptic effects
  - serotonergic receptors
- Primate, 799**
  - auditory threshold
  - baboon
  - pentobarbital
  - reaction time
  - visual threshold

Procaine, 49  
   abuse liability  
   cocaine  
   reinforcing efficacy  
   Rhesus monkey  
 Prolactin-induced grooming, 61  
   haloperidol  
   6-hydroxydopamine  
   nigrostriatal dopaminergic system  
 Prostaglandin E<sub>2</sub>, 657  
   body temperature  
   hyperthermia  
   hypothermia  
 Prostaglandin F<sub>2α</sub>, 657  
   body temperature  
   hyperthermia  
   hypothermia  
 Prostaglandins  
   angiotensin II, 263  
   body temperature, 263  
   cellular dehydration, 263  
   conditioned taste aversion, 263  
   drinking, 263  
   hypovolemia, 263  
   stress-induced eating, 735  
   tail pinch, 735  
   water deprivation, 263  
 Protein binding, 969  
   circadian rhythm  
   DSIP  
   immunoreactivity  
   radioimmunoassay  
 Protein synthesis inhibition  
   active avoidance, 289  
   amnesia, 489  
   anisomycin, 289  
   axoplasmic transport inhibition, 289  
   colchicine, 289  
   cycloheximide, 489  
   memory, 289  
   passive avoidance, 289  
   podophyllotoxin, 289  
   puromycin, 489  
   vinblastine, 289  
 Proteinase digestion, 449  
   liver  
   mercury  
   selenium  
 Punished and unpunished responding, 145  
   ketamine  
   pentobarbital  
   phencyclidine  
   pigeon  
 Punished responding, 743  
   amphetamine  
   bupropion  
   methylphenidate  
   minimal brain dysfunction  
 Punishment responding, 351  
   amphetamine  
   chlordiazepoxide  
   cyproheptadine  
   dorsal periaqueductal gray  
   methysergide  
   pentobarbital  
 Puromycin, 489  
   amnesia  
   protein synthesis inhibition  
  
 Quinine  
   drinking, 435  
 Quipazine  
   aggression, 149  
   apomorphine, 149, 895  
   chick, 895  
   DOM, 659  
   dopamine metabolites, 933  
   dopamine receptors, 933  
   dopaminergic mechanisms, 895  
   fenfluramine, 895  
   hallucinogens and operant responding, 659  
   head-shakes, 937  
   head twitches, 149  
   5-hydroxytryptamine, 659  
   metergoline, 659  
   morphine, 895  
   pergolide, 933  
   REM sleep, 937  
   REM sleep deprivation, 149  
   serotonergic activity, 937  
   serotonergic model, 895  
   serum corticosterone, 933  
   slow-wave sleep, 937  
   tonic immobility, 895  
  
 Radioimmunoassay, 969  
   circadian rhythm  
   DSIP  
   immunoreactivity  
   protein binding  
 Rate dependency, 723  
   C57BL/6J mice  
   locomotor activity  
   phenobarbital  
 Rauwolfia alkaloids, 911  
   amnesia  
   biogenic amines  
   brain catecholamine levels  
   guanethidine  
 Reaction time, 799  
   auditory threshold  
   baboon  
   pentobarbital  
   primate  
   visual threshold  
 Reactivity, 875  
   caffeine  
   stimulants  
   tactile startle  
 Receptor characterization, 975  
   antidepressants  
   calcium  
   imipramine  
   phospholipase A  
   platelets, human  
   tricyclics  
 Reinforcement, 539  
   concurrent schedules  
   drinking  
   ethanol  
 Reinforcement, fixed consecutive number, 609  
   dopamine and reward  
   pigeon  
   pimozide  
   stimulus control  
 Reinforcing efficacy, 49  
   abuse liability  
   cocaine  
   procaine  
   Rhesus monkey  
 REM sleep, 937  
   head-shakes  
   quipazine  
   serotonergic activity  
   slow-wave sleep  
 REM sleep deprivation, 149  
   aggression  
   apomorphine

- head twitches
- quipazine
- Renin, 879
  - aldosterone
  - ethanol
  - sodium balance
- Reserpine, 911
  - amnesia
  - brain catecholamine levels
- Reserpine-induced hypokinesia, 779
  - Huntington's disease
  - Parkinsonism
  - $\Delta^9$ -tetrahydrocannabinol
- Reserpine-induced hypothermia
  - MIF-1 and analogs, 983
- Restraint, 43
  - anticipatory responding
  - chlorpromazine
  - escape
  - fixed-time schedule
- Retention, 247
  - acquisition
  - etiracetam
  - extinction
  - open field
  - passive avoidance
  - piracetam
- Reticular formation, 21
  - arecoline
  - central nervous system
  - drug discrimination
  - hippocampus
  - nicotine
- Retrograde amnesia
  - D-glutamine, 367
- Reward
  - dopamine receptor blockade, 435
  - pimozide, 435
  - pimozide and learning, 655
  - quinine, 435
- Reward and reward omission, 227
  - electrical brain stimulation
  - fixed-interval behavior
  - food
  - neuroleptics
  - pimozide
- Rhesus monkey
  - abuse liability, 49
  - buprenorphine, 215
  - cocaine, 49, 141
  - drug physical dependence, 215
  - drug reinforcement, 215
  - drug self-administration, 141, 215
  - food deprivation, 141
  - procaine, 49
  - reinforcing efficacy, 49
- Ro 4-4602, 871
  - brain serotonin
  - ethanol intake
  - 5-hydroxytryptophan
- Rotational behavior, 687
  - carbachol
  - caudate nucleus
  - dopamine
  - dopaminergic-cholinergic interaction
  - globus pallidus
  - oxotremorine
  - substantia nigra
- Salivation, 197
  - catecholamines
  - p*-chloroamphetamine
  - ejaculation
  - 5-hydroxytryptamine levels
- hypothermia
- irritability
- thermoregulation
- Satiety, 179
  - clorgyline
  - eating
  - locomotor activity
  - sensorimotor performance
  - serotonin
- Schedule
  - cocaine self-administration, 485
- Schedule-controlled behavior, 415
  - clozapine
  - fixed interval
  - shock
  - squirrel monkey
  - stimulus-shock termination
- Schedule-controlled responding, 65
  - narcotic antagonists
  - phenylpiperidine
  - pigeon
- Schizophrenia, 903
  - brain-stimulation reward
  - chlorpromazine
  - enkephalin
  - naloxone
- Scopolamine
  - acetylcholinesterase activity, 517
  - aversive drug stimulus, 389
  - choline acetyltransferase activity, 517
  - location avoidance, 389
  - muricide, 517
  - olfactory bulbectomy, 517
- Sedation, 695
  - animal model
  - antidepressants
  - anxiolytics
  - benzodiazepines and behavior
  - exploration
  - locomotion
  - neuroleptics
- Seizures
  - activity, 545
  - AMPA, 545
  - amygdaloid kindling, 533
  - body temperature, 545
  - catalepsy, 545
  - pentylentetrazol sensitization transfer, 533
  - wet dog shakes, 545
- Selective attention, 81
  - activity levels
  - distractability
  - exploration
  - lithium chloride
- Selenium, 449
  - liver
  - mercury
  - proteinase digestion
- Self-stimulation
  - bar press, 767
  - brain-stimulation reward, 915
  - central gray, 37
  - clonidine, 767
  - conditioned taste preference, 915
  - dopamine receptor antagonism, 915
  - haloperidol, 767
  - lateral hypothalamus, 37
  - methocarbamol, 767
  - morphine, 37
  - nose poke, 767
  - pentobarbital, 767
  - pimozide, 915
- Sensitization
  - chronic amphetamine, 161
  - cocaine, 559

- osmotic minipumps, 161
- Pavlovian conditioning, 559
- stereotypy, 161
- tolerance, 161
- Sensorimotor performance, 179
  - clorgyline
  - eating
  - locomotor activity
  - satiety
  - serotonin
- Sensory-motor function, 7
  - activity level
  - behavior
  - drinking
  - phencyclidine
  - taste aversion
- Serotonergic activity, 937
  - head-shakes
  - quipazine
  - REM sleep
  - slow-wave sleep
- Serotonergic model, 895
  - apomorphine
  - chick
  - dopaminergic mechanisms
  - fenfluramine
  - morphine
  - quipazine
  - tonic immobility
- Serotonergic receptors, 125
  - animal model, depression
  - antidepressants
  - postsynaptic effects
  - presynaptic effects
- Serotonin
  - brainstem auditory evoked responses, 587
  - cat, 711
  - cerebellum, 951
  - cerebral cortex, 951
  - chronic iprindole, 951
  - clorgyline, 179
  - dopamine, 711, 951
  - eating, 179
  - epilepsy, 363
  - limb flicking, 711
  - lisuride, 711
  - locomotor activity, 179
  - LSD, 711
  - mesencephalon, 951
  - monoamine oxidase inhibition, 951
  - nicotine-induced depression, 587
  - norepinephrine, 951
  - satiety, 179
  - sensorimotor performance, 179
  - yawning, 711
- Serum corticosterone, 933
  - dopamine metabolites
  - dopamine receptors
  - pergolide
  - quipazine
- Sex differences
  - drinking, 921
  - escape, 33
  - ethanol dependence, 55
  - ethanol liquid diet, 55
  - ethanol sensitivity, 33
  - MIF-I and analogs, 921
  - naloxone, 921
  - pharmacogenetics, 33
  - task dependency, 33
  - withdrawal, 55
- Sexual behavior
  - 8-hydroxy-2-(di-n-propylamino)tetralin, 785
  - 5-hydroxytryptamine receptors, 785
  - LHRH analog, 961
  - lor dosis, 961
  - 8-methoxy-2-(di-n-propylamino)tetralin, 785
  - ovulation inhibition, 961
  - sexual receptivity, 961
- Sexual behavior, female, 761
  - adrenalectomy
  - corticosterone
  - estrogen-induced lordosis
  - ovariectomy
- Sexual receptivity, 961
  - LHRH analog
  - lordosis
  - ovulation inhibition
  - sexual behavior
- Shock, 415
  - clozapine
  - fixed interval
  - schedule-controlled behavior
  - squirrel monkey
  - stimulus-shock termination
- Shock-induced aggression
  - cyproterone acetate, 691
  - endorphins, 513
  - 5-hydroxyindoleacetic acid, 691
  - 5-hydroxytryptophan, 691
  - inbred mice, 513
  - naloxone, 513
  - phencyclidine, 813
  - plasma testosterone levels, 691
- Short-term memory
  - amphetamine, 673
- Slow-wave sleep, 937
  - head-shakes
  - quipazine
  - REM sleep
  - serotonergic activity
- Social behavior, mice, 281
  - endocrine receptivity
  - exteroceptive stimuli
  - hypothalamic-pituitary-gonadal axis
  - luteinizing hormone releasing factor
  - pheromones
  - testosterone
  - $\Delta^9$ -tetrahydrocannabinol
- Sodium balance, 879
  - aldosterone
  - ethanol
  - renin
- Sodium depletion, 1
  - 5-hydroxytryptamine
  - noradrenaline
  - sodium load
- Sodium load, 1
  - 5-hydroxytryptamine
  - noradrenaline
  - sodium depletion
- Sodium valproate, 681
  - benzodiazepine
  - visual evoked potentials
- Sotalol, 597
  - $\beta$ -antagonists and amnesia
  - passive avoidance learning
- Spectral analysis, 627
  - amphetamine behavior assessment
  - capacitance transducer
- Squirrel monkey
  - catalepsy, 243
  - clozapine, 415
  - dopamine, 243
  - fixed interval, 415
  - locomotor activity, 243
  - nucleus accumbens, 243
  - schedule-controlled behavior, 415
  - shock, 415
  - stimulus-shock termination, 415

Starvation  
   body temperature, 551  
   dietary lead and hyperactivity, 505  
   ethanol, 551  
   food deprivation, 551  
   hyperglycemia, 551  
   hyhoglycemia, 551  
 Stereospecific opiate agonists and antagonists, 591  
   drinking  
   eating  
   hyperdipsia  
   hyperphagia  
   opiate peptides  
 Stereotypy  
   apomorphine, 521  
   chronic amphetamine, 161  
   licking, 521  
   methamphetamine, 521  
   osmotic minipumps, 161  
   sensitization, 161  
   sniffing, 521  
   tolerance, 161  
 Stimulants, 875  
   caffeine  
   reactivity  
   tactile startle  
 Stimulus control, 157  
   aminophylline  
   caffeine  
 Stimulus properties of drugs, 907  
   coca  
   cocaine  
 Stimulus-shock termination, 415  
   clozapine  
   fixed interval  
   schedule-controlled behavior  
   shock  
   squirrel monkey  
 Strain differences, 173  
   Animex motimeter  
   catecholamine concentration and turnover  
   circadian rhythm  
   motor activity  
 Stress, 235  
   circadian rhythms  
   phenobarbital  
   phenytoin  
   plasma corticosterone levels  
 Stress-induced analgesia, 853  
   endogenous opiates  
   Leu-enkephalin  
   opiate receptors  
 Stress-induced eating, 735  
   prostaglandins  
   tail pinch  
 Striatal dopamine  
   neonatal lead exposure, 641  
 Structure-activity relationships, 27  
   endorphins  
   footshock  
    $\beta$ -lipotropin fragments  
 Substantia nigra  
   d-amphetamine, 75  
   carbachol, 687  
   clorgyline, 75  
   deprenil, 75  
   l-dopa, 75  
   dopamine, 687  
    $^3\text{H}$ -dopamine release, 75  
    $^3\text{H}$ -dopamine uptake, 75  
   dopaminergic-cholinergic interaction, 687  
   lesions, 6-OHDA, 75  
   oxotremorine, 687  
   Parkinsonism, 75  
   rotational behavior, 687  
   Sweetness perception receptor sites, 377  
     cross adaptation  
     multidimensional scaling  
 Syrosingopine, 911  
   amnesia  
   brain catecholamine levels  
 Tactile startle, 875  
   caffeine  
   reactivity  
   stimulants  
 Tail pinch, 735  
   prostaglandins  
   stress-induced eating  
 Task dependency, 33  
   escape  
   ethanol sensitivity  
   pharmacogenetics  
   sex differences  
 Taste aversion, 7  
   activity level  
   behavior  
   drinking  
   phencyclidine  
   sensory-motor function  
 Testosterone, 281  
   endocrine responsiveness  
   exteroceptive stimuli  
   hypothalamic-pituitary-gonadal axis  
   luteinizing hormone releasing factor  
   pheromones  
   social behavior  
    $\Delta^9$ -tetrahydrocannabinol  
 $\Delta^9$ -Tetrahydrocannabinol  
   endocrine responsiveness, 281  
   exteroceptive stimuli, 281  
   Huntington's disease, 779  
   hypothalamic-pituitary-gonadal axis, 281  
   luteinizing hormone releasing factor, 281  
   Parkinsonism, 779  
   pheromones, 281  
   reserpine-induced hypokinesia, 779  
   social behavior, mice, 281  
   testosterone, 281  
 Thermoregulation, 197  
   catecholamines  
   *p*-chloroamphetamine  
   ejaculation  
   5-hydroxytryptamine levels  
   hypothermia  
   irritability  
   salivation  
 Thirst, 337  
   angiotensin  
   vena cava ligation  
 Timolol, 597  
    $\beta$ -antagonists and amnesia  
   passive avoidance learning  
 Tolerance  
   analgesia, 637  
   behavioral tolerance, 637  
   chick embryo, 773  
   chronic amphetamine, 161  
   Formalin test, 637  
   morphine, 637, 773  
   osmotic minipumps, 161  
   pain, 637  
   sensitization, 161  
   stereotypy, 161  
   tonic pain, 637  
 Tolerance and reverse tolerance, 399  
   amphetamine  
   chronic administration and behavioral effects  
   dopaminergic function

- Tonic immobility
  - alpha-adrenergic antagonists, 739
  - animal hypnosis, 739
  - apomorphine, 895
  - chick, 895
  - chicken, 739
  - dopaminergic mechanisms, 895
  - fenfluramine, 895
  - morphine, 895
  - phentolamine, 739
  - prazosin, 739
  - quipazine, 895
  - serotonergic model, 895
  - yohimbine, 739
- Tonic pain, 637
  - analgesia
  - behavioral tolerance
  - Formalin test
  - morphine
  - pain
  - tolerance
- Tricyclics, 975
  - antidepressants
  - calcium
  - imipramine
  - phospholipase A
  - platelets, human
  - receptor characterization
- Tryptophan
  - brain serotonin, 201
  - drinking, 201
  - eating, 201
  - locomotion, 201
  - muricide, 201, 343
  - septal lesions, 343
- Urination, 297
  - body weight
  - p*-chloroamphetamine
  - defecation
- Vena cava ligation, 337
  - angiotensin
  - thirst
- Ventral tegmental area, 583
  - intracranial self-stimulation
  - naloxone
  - pentobarbital
- Ventromedial hypothalamic hyperphagia, 15
  - diet palatability
  - eating
  - norepinephrine-induced feeding
- Ventromedial hypothalamus, 555
  - dopamine
  - morphine-induced feeding
  - norepinephrine
  - phentolamine
- Vinblastine, 289
  - active avoidance
  - anisomycin
  - axoplasmic transport inhibition
  - colchicine
  - memory
- passive avoidance
- podophyllotoxin
- protein synthesis inhibition
- Visual evoked potentials, 681
  - benzodiazepine
  - sodium valproate
- Visual threshold, 799
  - auditory threshold
  - baboon
  - pentobarbital
  - primate
  - reaction time
- Water deprivation
  - angiotensin II, 263
  - body temperature, 263
  - Brattleboro rat, 109
  - cellular dehydration, 263
  - conditioned taste aversion, 263
  - diabetes insipidus, 109
  - drinking, 109, 257, 263, 319
  - endorphins, 257, 319
  - gastric fistulas, 319
  - hypovolemia, 263
  - lateral hypothalamus, 257
  - lateral ventricles, 257
  - naloxone, 109, 257, 319
  - prostaglandins, 263
- Wet dog shakes, 545
  - activity
  - AMPA
  - body temperature
  - catalepsy
  - seizures
- Wheel-running, 819
  - activity level
  - ethanol
- Withdrawal
  - drug self-administration, 101
  - ethanol dependence, 55, 101
  - ethanol liquid diet, 55
  - methadone, 887
  - naloxone, 887
  - opiates, 887
  - perinatal exposure, 887
  - sex differences, 55
- Yawning, 711
  - cat
  - dopamine
  - limb flicking
  - lisuride
  - LSD
  - serotonin
- Yohimbine, 739
  - alpha-adrenergic antagonists
  - animal hypnosis
  - chicken
  - phentolamine
  - prazosin
  - tonic immobility

## AUTHOR INDEX

- ABBOTT, F. V., 637  
ADVOKAT, C., 677  
AHLENIUS, S., 785  
AIGNER, T., 49  
ALAM, M. R., 925  
ALDRICH, S., 739  
ALEXANDER, B. K., 571  
ALLEN, D. L., 55  
AMIT, Z., 651, 755  
ANDERSON, G. M., 443  
ANDREW, R. J., 597  
APFELBAUM, M., 89  
APRISON, M. H., 125  
ARTMAN, L. D., 271  
ARVIDSSON, L.-E., 785
- BACOTTI, A. V., 415  
BAEZ, A. M., 819  
BAIZER, L., 945  
BANKS, W. A., 969  
BARR, G. A., 201  
BARRACO, D. A., 489  
BARTKE, A., 281  
BASS, M. B., 33  
BATTER, D. K., 443  
BEDFORD, J. A., 907  
BEER, B., 965, 975  
BENNETT, E. L., 289  
BERG, S. L., 243  
BERGMAN, J., 141  
BERMUDEZ-RATTONI, F., 257  
BEYERSTEIN, B. L., 571  
BHARGAVA, V., 537, 587  
BIERLEY, R. A., 673  
BIRD, K. D., 853  
BLACKMAN, D. E., 227  
BLACKWELL, L. A., 723  
BLAIR, R., 651  
BLAMPIED, N. M., 389  
BLUTH, R., 987  
BOGGAN, W. O., 723  
BOHUS, B., 61  
BORRELL, J., 235  
BORRELL, S., 235  
BRADY, J. V., 799  
BREE, M. P., 215  
BREESE, G. R., 743  
BRIDGER, W. H., 201  
BRITTON, D. R., 577  
BRITTON, K. T., 577  
BROWN, D. R., 109  
BROWN, O. M., 911  
BURCH, J. B., 271
- CABBAT, F. S., 75  
CAHN, H., 377  
CAIN, D. P., 533  
CALDER, L. D., 7  
CAMPOS, C. J. R., 363  
CANONICO, P. L., 61  
CAPPELIEZ, P., 81  
CARL, E. B., 739  
CARLSON, K. R., 583  
CARLSSON, A., 785  
CARNEY, J. M., 323  
CARRANZA, J., 951  
CASPARI-IRVING, G., 173  
CASTELLANO, C., 729  
CASTELLANOS, P. F., 969  
CASTRO-OSUNA, G., 951  
CAVALHEIRO, E. A., 363  
CHAIT, L. D., 145  
CHAN, A. W. K., 185  
CHERKIN, A., 367  
CHESHER, G. B., 849, 853  
CHIARAVIGLIO, E., 1  
CHRISTEN, H., 717  
CHRISTENSEN, H. D., 323  
CHRISTIE, M. J., 849, 853  
CLEARY, J., 43, 357, 813  
COAMBS, R. B., 571  
COHEN, D. J., 443  
COLE-HARDING, L. S., 55  
COLLINS, A. C., 271  
COLPAERT, F. C., 515  
COMMISSARIS, R. L., 659  
COUPAL, A., 37  
COUPET, J., 965  
COWAN, A., 135  
COY, D. H., 845, 921, 955, 961, 969, 983  
CRAWLEY, J. N., 695  
CUMIN, R., 115  
CZUCZWAR, S. J., 545
- DAIRMAN, W., 303  
DALTERIO, S., 281  
DARGIE, C. M., 257  
DAVIS, J. L., 367  
DE AGUIAR, J. C., 351  
DECATANZARO, D., 761  
DE LA GARZA, R., 141  
DELATTE, S. W., 921  
DILL, R. E., 243  
DORRIS, R. L., 243  
DRAGO, F., 61  
DUCKETT, S., 495
- DUKA, TH., 115  
DUNCAN, P. M., 819  
DUNN, A. J., 605  
DUVOISIN, R. C., 75
- EICHELMAN, B., 343  
EISENSTEIN, E. M., 489  
ELISABETSKY, E., 363  
ELLINWOOD, E. H., JR., 627  
ELSOHLY, H. N., 907  
ESPARZA-AVALOS, N. S., 951  
ESPOSITO, R. U., 903  
ERICKSON, D. G., 921  
ETTENBERG, A., 915
- FABRE, L. A., 961  
FALK, J. L., 471  
FAUSTMAN, W. O., 327  
FAZIO, J. K., 739  
FERNANDEZ, R. C., 921  
FIBIGER, H. C., 619  
FIGUEROA, M., 633  
FINK, H., 987  
FLOOD, J. F., 289  
FOBES, J. L., 167  
FOLTIN, R. W., 71  
FORNAL, C., 937  
FOWLER, S. C., 327  
FRANKLIN, K. B. J., 637  
FULLER, R. W., 933  
FYHRQUIST, F., 879
- GANTEN, D., 337  
GARCIA, J., 845  
GAULT, F., 43  
GELLER, I., 871  
GENEST, J., 337  
GE-HHARDT, S., 767  
GEYER, M. A., 875  
GIBBONS, J. L., 201  
GLUSMAN, M., 747  
GMEREK, D. E., 135  
GOLDSTEIN, B. D., 501  
GOLUS, P., 883  
GOODMAN, I. J., 701  
GÓRKA, Z., 657  
GORZALKA, B. B., 761  
GOWDEY, C. W., 555  
GRAEFF, F. G., 351  
GRAF, M., 717  
GREENSHAW, A. J., 227  
GUAZA, C., 235  
GUILD, A. L., 605



GUZMÁN-AMAYA, P., 951

HACKSELL, U., 785  
HADAWAY, P. F., 571  
HAEFELY, W., 115  
HARDING, J. W., 521  
HARDY, J. D., 7  
HARTEL, C. R., 141  
HARTLINE, R. A., 495  
HARTMANN, R. J., 871  
HASTINGS, D. B., 921  
HAYES, M., 845  
HEGSTRAND, L. R., 343  
HEIKKILA, R. E., 75  
HENDRICKS, C., 793  
HENNIG, C. W., 739  
HERAKOVIC, J., 813  
HERMAN, B. H., 477  
HERZ, A., 115  
HIENZ, R. D., 799  
HINGTGEN, J. N., 125  
HINSON, R. E., 559  
HIRABAYASHI, M., 925  
HIRST, M., 555  
HJORTH, S., 785  
HOLLOWAY, F. A., 323  
HOLTZMAN, S. G., 109  
HONOUR, L. C., 983  
HOWE, S. M., 185  
HUGHES, C. A., 739  
HUGHES, R. N., 389  
HUMPHRIES, C. R., 197  
HUNT, T., 755  
HUTCHINS, J. B., 55

IMURA, N., 449

JACKSON, K., 357  
JALOWIEC, J. E., 477  
JARVIK, M. E., 289  
JASON, K. M., 641  
JENDEN, D. J., 285  
JOHANSON, C. E., 49  
JOHNSON, A. K., 337, 563  
JOHNSON, J. H., 419  
JONES, D. L., 243  
JORK, R., 705

KANTAK, K. M., 297, 343  
KASTIN, A. J., 845, 921, 955, 961,  
969, 983  
KATZ, R. J., 131  
KELLOGG, C. K., 641  
KENNEY, N. J., 263  
KESNER, R. P., 7, 673  
KING, M. G., 883  
KLEINROK, Z., 545  
KNIPPING, R. P., 761  
KOFMAN, O., 93  
KORNETSKY, C., 903  
KRAMARCY, N. R., 605  
KUCZENSKI, R., 399, 405  
KUTSCHER, C. L., 505, 663

LANDRY, D. W., 289  
LARSSON, K., 785  
LAU, C. E., 471  
LEANDER, J. D., 65  
LEIBOWITZ, S. F., 201  
LEITH, N. J., 399, 405  
LEMMER, B., 173  
LEONG, F. W., 185  
LESHEM, M., 859  
LESTER, D., 33  
LEVINE, A. S., 735

LEVY, R. A., 501  
LIEBMAN, J. M., 393, 767  
LIND, R. W., 563  
LINDBERG, P., 785  
LINDLEY, M. G., 377  
LINKOLA, J., 879  
LIPPA, A. S., 965  
LIPTON, S. V., 443  
LOCHRY, E. A., 191  
LÖSSNER, B., 705  
LOVELL, K. L., 489  
LOWY, M. T., 591  
LUDWICK, R. J., 637  
LUKAS, S. E., 799

McLAUGHLIN, P. J., 887  
McMASTER, S. B., 779  
McMILLAN, D. E., 145

MacMAHON, S. W., 389  
MAIER, P. F., 717  
MANDENOFF, A., 89  
MANN, J. F. E., 337  
MANZINO, L., 75  
MARINI, J. L., 711, 865  
MARKS, M. J., 271  
MASSERANO, J. M., 945  
MASUR, J., 551  
MATTHIES, H., 705  
MAYER, D. J., 419  
MAYFIELD, D., 281  
MELLO, N. K., 215  
MELTZER, L. T., 21  
MELZACK, R., 637  
MENDELSON, J. H., 215  
MENS, W. B. J., 27  
MESSIHA, F. S., 871  
MEYERSON, L. R., 975  
MIDDAUGH, L. D., 723  
MILLER, L. H., 845  
MINTZ, M., 93  
MODROW, H. E., 323  
MOE, K. E., 263  
MOERSCHBAECHER, J. M., 807  
MOGILNICKA, E., 149  
MOLTER, D. W., 627  
MORAG, M., 681  
MORATO DE CARVALHO, S., 351  
MORGENSTERN, R., 987  
MORLEY, J. E., 735  
MOSELEY, J. W., 191  
MOSS, D. E., 779  
MUELLER, R. A., 743  
MUNARO, N., 1  
MURRAY, R. B., 135  
MYSLOBODSKY, M. S., 93, 681

NAGANUMA, A., 449  
NAGAYAMA, H., 125  
NAIL, G. L., 907  
NAJAM, N., 477  
NAZZARO, J. M., 583  
NEWBY-SCHMIDT, M. B., 773  
NIELSEN, E. B., 161  
NIEMINEN, M. M., 879  
NILSSON, J. L. G., 785  
NISSSEN, C., 955  
NOREIKA, L., 393  
NORTON, S., 773  
NUMAN, R., 101

O'BRIEN, M., 197  
OEI, T. P. S., 485  
OLDS, M. E., 167  
OLIVEIRA DE SOUZA, M. L., 551

OLIVERIO, A., 513  
OLSON, G. A., 921  
OLSON, R. D., 921  
ORTEGA-CORONA, B. G., 951

PALFAI, T., 911  
PANKSEPP, J., 477  
PAPASAVA, M., 485  
PAPPAS, B. A., 743  
PASTOR, G., 393  
PATINKIN, D. M., 271  
PAXINOS, G., 197  
PEBBLES, P., 673  
PERRY, W., 903  
PETTY, F., 567  
PINEL, J. P. J., 619  
POLING, A., 357, 813  
POLLARE, T., 875  
POLLOCK, J. D., 179  
POTEGAL, M., 747  
POULOS, C. X., 559  
PRADO-ALCALÁ, R. A., 633  
PRASAD, V., 691  
PRESTON, K. L., 71, 827  
PUGLISI-ALLEGRA, S., 513  
PUSHPAVATI, C. P., 537

RADULOVACKI, M., 937  
RANDALL, C. L., 191  
RASCHER, W., 337  
RAUH, C. E., 965  
RECH, R. H., 659  
REID, L. D., 257, 319  
ROCKWOOD, G. A., 257, 319  
ROEHRS, T. A., 539  
ROGERS, J., 779  
ROSECRANS, J. A., 21  
ROWLAND, N., 179  
RUSSELL, R. W., 285

SALAMY, A., 587  
SALZMAN, S. K., 119  
SAMSON, H. H., 539  
SANCHEZ, D., 785  
SANGER, D. J., 227  
SCAPAGNINI, U., 61  
SCHANLEY, D. L., 185  
SCHECHTER, M. D., 371  
SCHENK, S., 37  
SCHIFFMAN, S. S., 377  
SCHNEIDER, C. W., 495  
SCHOENENBERGER, G. A., 717  
SCHULZ, E. M., 521  
SCHUSTER, C. R., 71, 827  
SCHWARTZ, H. V., 655  
SCLAFANI, A., 15, 435  
SEEGER, T. F., 583  
SEGAL, S. A., 807  
SEWELL, R., 43  
SHAH, S., 587  
SHAYWITZ, B. A., 443  
SHEARD, M. H., 691  
SHERMAN, A. D., 567  
SHIZGAL, P., 37  
SIGNORET, L., 633  
SINGER, G., 485  
SIVIY, S. M., 257, 319  
SKAREDOFF, L., 747  
SKOOG, K. M., 263  
SNODDY, H. D., 933  
SOSA, A., 951  
SPLAWINSKI, J., 657  
SPRATTO, G. R., 425  
STARKEY, C., 591  
STAUDERMAN, K. A., 627

STEIN, J. M., 297  
STEPHENSON, R. M., 597  
STEPITA-KLAUCO, M., 119  
STERSTE, A., 845  
STRIPLING, J. S., 793, 823  
SULLIVAN, A. C., 303, 311  
SUTKER, P. B., 191  
SVENSSON, L., 785  
SWAJKOSKI, A. R., 419  
SWITZMAN, L., 755  
SZOSTAK, C., 609

TALLARIDA, R. J., 135  
TANG, M., 471  
TEICHER, M. H., 443  
TEPPERMAN, F. S., 555  
THOMPSON, D. M., 807  
TIKKANEN, I., 879  
TOBLER, H. J., 717  
TOMBAUGH, J. W., 455  
TOMBAUGH, T. N., 455, 463, 609  
TONTTI, K., 879  
TORIS, J. A., 15  
TORRELLAS, A., 235  
TREIT, D., 619  
TRISCARI, J., 303, 311

TURNER, C. E., 907  
TURSKEI, L., 545  
TURSKEI, W., 545

VAN DEN HOOGEN, R. H. W. M.,  
515  
VAN REE, J. M., 27  
VOGEL, R. A., 743  
VON ALMEN, T. K., 921

WAGNER, G. C., 71  
WALLACE, S., 357  
WALLNAU, L. B., 895  
WARD, H. W., 875  
WARE, M. D., 605  
WAYNER, M. J., 297  
WEIMER, R., 173  
WEINER, N., 945  
WENGER, G. R., 145  
WENNOGLE, L. P., 975  
WESTERMANN, K. H., 687  
WHITE, N., 81, 915  
WICHLINSKI, L., 911  
WIECHMAN, B. E., 425  
WIKSTRÖM, H., 785  
WILLIAMS, T., 37

WILSON, J. H., 743  
WILSON, J. R., 55  
WILSON, M. C., 907  
WINTER, J. C., 157  
WISE, R. A., 655  
WOJTASZEK, B., 657  
WOLTHUIS, O. L., 247  
WOOD, T. E., 425  
WRIGHT, J. W., 521

XENAKIS, S., 435

YAMAMOTO, B. K., 505, 663  
YIM, G. K. W., 591  
YOBURN, B. C., 747  
YORK, J. L., 207  
YOSHIMURA, H., 517  
YOUNG, J. G., 443

ZADINA, J. E., 961  
ZAGON, I. S., 887  
ZEMP, J. W., 723  
ZINGARELLI, G. J., 849  
ZOLOVICK, A. J., 477